

1

2

STATE OF CALIFORNIA

3
FORCE

MANAGED HEALTH CARE IMPROVEMENT TASK

4

5

6

7

8

TRANSCRIPT OF PROCEEDINGS

9

10

**STATE OF CALIFORNIA
MANAGED HEALTH CARE IMPROVEMENT TASK FORCE**

11

**Business Meeting
Friday, June 20, 1997
2550 Mariposa Mall
Fresno, California 93271**

12

13

14

15

Morning Session - 10:00 a.m.

16

17

18

19

20

21

22

23

24

REPORTED BY:

25

**Kimberlee R. Miller,
CSR No. 10869**

26

Our File No. 37162

27

28

1 APPEARANCES:

2

3 Alain C. Enthoven - Chairman

4 Dr. Phil Romero - Executive Director

5 Alice M. Singh - Deputy Director

6 Jill C. McLaughlin - Administrative Assistant

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

1 **MR. ENTHOVEN:** The meeting will come to
2 order. I'd like to begin by asking Ms. Jill McLaughlin to
3 call the roll. Jill.

4 **MS. MCLAUGHLIN:** Will the following members
5 please signify their attendance by stating present.

6 **Alpert.**

7 **DR. ALPERT:** Present.

8 **MS. MCLAUGHLIN:** Armstead.

9 **Bowne.**

10 **MS. BOWNE:** Here.

11 **MS. MCLAUGHLIN:** Conom.

12 **Decker.**

13 **MS. DECKER:** Here.

14 **MS. MCLAUGHLIN:** Enthoven.

15 **MR. ENTHOVEN:** Here.

16 **MS. MCLAUGHLIN:** Farber.

17 **Finberg.**

18 **MS. FINBERG:** Here.

19 **MS. MCLAUGHLIN:** Gallegos.

20 **Gilbert.**

21 **Griffiths.**

22 **Hartshorn.**

23 **MR. HARTSHORN:** Here.

24 **MS. MCLAUGHLIN:** Hauck.

25 **MR. HAUCK:** Here.

26 **MS. MCLAUGHLIN:** Hiepler.

27 **MR. HIEPLER:** Here.

28 **MS. MCLAUGHLIN:** Karpf.

1 **DR. KARPFF: Here.**

2 **MS. MCLAUGHLIN: Kerr.**

3 **MR. KERR: Present.**

4 **MS. MCLAUGHLIN: Lee.**

5 **MR. LEE: Here.**

6 **MS. MCLAUGHLIN: Murrell.**

7 **Northway.**

8 **O'Sullivan.**

9 **Perez.**

10 **MR. PEREZ: Here.**

11 **MS. MCLAUGHLIN: Ramey.**

12 **Rodgers.**

13 **MR. RODGERS: Here.**

14 **MS. MCLAUGHLIN: Rodrigues-Trias.**

15 **DR. RODRIGUES-TRIAS: Here.**

16 **MS. MCLAUGHLIN: Severoni.**

17 **MS. SEVERONI: Here.**

18 **MS. MCLAUGHLIN: Spurlock.**

19 **DR. SPURLOCK: Here.**

20 **MS. MCLAUGHLIN: Tirapelle. Tirapelle.**

21 **Williams.**

22 **MR. WILLIAMS: Here.**

23 **MS. MCLAUGHLIN: Zaremborg.**

24 **MR. ZAREMBERG: Here.**

25 **MS. MCLAUGHLIN: Zarkin.**

26 **MR. ZATKIN: Here.**

27 **MS. MCLAUGHLIN: Thank you.**

28 **MR. ENTHOVEN: A quorum is present so we'll**

1 proceed with the meeting.

2 As an ongoing effort to educate the Task
3 Force about various aspects of managed care, today's
4 program is about consumer protection as implemented by
5 managed health care plans and will focus on two issues:
6 Managed care environment around 1975 when the Knox-Keene
7 Act was enacted, and a discussion of the Act's objectives
8 and how it's been progressing; and then the second part
9 will be a discussion consumer involvement communication
10 and information.

11 We validated about 45 minutes of meeting
12 time to each of these topics. On the first one Mr. Keith
13 Bishop and Mr. Warren Barnes with the Department of
14 Corporations will present the section on the Knox-Keene
15 Act and task force member -- so Mr. Barnes and Mr. Bishop,
16 thank you for coming.

17 MR. BISHOP. Thank you Mr. Chairman and as I
18 said I'm Keith Bishop and to my right is Warren Barnes.
19 Warren will speak first about the history and sort of
20 antecedents of the Knox-Keene Act in California.

21 MR. BARNS: I will review, in very
22 broad-breast fashion, historical information that
23 virtually all of you are already familiar and put the
24 Knox-Keene Act in some historical perspective.

25 The thread that runs through the history of
26 managed care in California preceding and during the
27 Knox-Keene Act era relates to problems associated with
28 changes in financial incentives, in my judgment.

1 In the 1930s, you will recall was the first
2 era of managed care, or in those days prepaid care in
3 California. After a large number of companies were in
4 business for a period, there was an enormous shake out in
5 the marketplace, Kaiser and Ross Loose (phonetic) are two
6 of the notables that continue today, Ross Loose under the
7 name of Cigna at this time. Blue Cross also became
8 happily ensconced in Chapter 11 (a) of the Insurance Code
9 during the 1930s. There are other companies as well.

10 In the 1960s, there was then experienced a
11 resurgence of interest in managed care with a number of
12 new entrants into the market; that was a cause for concern
13 for some of the more established, obviously reputable
14 companies, and they on their own industry initiative came
15 together to seek legislation to regulate the managed care
16 industry well aware that major problems in one area could
17 tarnish the entire industry in the public mind. What
18 resulted from that in 1965 was the Knox-Mills Health Plan
19 Act that provided for registration of health care service
20 plans. The administrator was the Attorney General. The
21 regulatory program consisted of one person, by the name of
22 Bob Obress (phonetic), who collected the registration
23 statements that the plan submitted. Attorneys in the
24 A.G.'s office were available for consultation.

25 Then in the late '60s, as you well know,
26 then Governor Regan saw the wisdom of using prepayment as
27 a mode for delivery of medical services that resulted in a
28 large number of people entering the market for the first

1 time as prepaid health plans to serve the Medi-Cal
2 population. There were a number of significant problems
3 marketing quality of care, administration, etc., that were
4 observed at that time, which resulted in 1972 in the
5 enactment of the Waxman-Duffy Health Plan Act. That was
6 the first formal consistent statutory authority for the
7 Department of Health Services to contract with entities on
8 a prepaid basis to provide services to Medi-Cal enrollees
9 and also allowed DHS authority to monitor those contracts.

10 Now there were a number of problems that
11 became steadily worse over a period of time. It was
12 eminently clear, in retrospect, that the Knox-Mills Act of
13 1965 was utterly unsuited to, shall I say contain the
14 entrepreneurial ferment that was associated with that
15 prepaid health care, and in particular it was utterly
16 unsuited to contain the ferment involved with the
17 prepayment programs for Medi-Cal enrollees.

18 The Waxman-Duffy Act was widely understood
19 in the capital as the solution to the problem, at least
20 insofar as prepaid Medi-Cal was concerned. Unfortunately,
21 this did not turn out to be the case. Knox-Mills and
22 Waxman-Duffy together were unable to contain those
23 problems. As a consequence, the legislature in 1975
24 enacted the Knox-Keene Health Care Service Plan Act. That
25 act was designed to create a channel consisting of a
26 variety systems that Commissioner Bishop will discuss
27 later to regulate the health plan industry, commercial,
28 Medi-Cal all aspects of the prepaid or managed care

1 business.

2 At that time, the legislature was presented
3 with a problem. The attorney general had made it
4 abundantly clear that he wished to have no more to do with
5 the regulation of managed care. Consequently, it was
6 necessary for the legislature to define a home for the
7 Knox-Keene Act who would be the department in charge of
8 it, the administration, and enforcement responsibilities.
9 There were several considerations. In many states DOI
10 regulates -- the Department of Insurance in many states
11 regulates the managed care industry, that was rejected by
12 the California legislature on the grounds that the managed
13 care industry was a service industry exemplified by the
14 term health care service plan as opposed to an
15 indemnification industry and there was concern if the
16 managed care industry were saddled with insurance-style
17 regulation it would not be able to fulfill the objectives
18 that the legislature had in mind for it. In specific,
19 cost containment without deterioration and quality of
20 care.

21 DHS was also an obvious possibility. There
22 was concern with DHS that DHS was also a primary purchaser
23 of services insofar as the prepaid Medi-Cal programs were
24 concerned. That was a major hope for cost containment;
25 there was a concern there might be a conflict of interest,
26 it might be very difficult to encourage plans to contract
27 with them at the same time to regulate them. There was
28 less consideration given to Consumer Affairs, but the

1 perception was that Consumer Affairs, insofar as health is
2 concerned, is primarily related with regulating
3 professionals.

4 Department of Corporations ultimately was
5 selected for two reasons. First, the Department had a
6 long history of successful regulation of a large variety
7 of different types of businesses ranging from broker
8 dealers on the one hand to financial services companies
9 and a number of other entities through the continuum. The
10 second reason Department of Corporations was selected, is
11 that it had its own enforcement capability, enforcement
12 attorneys that worked over a wide variety, the entire
13 range of laws that the Department is responsible for
14 administering, approximately twelve or thirteen in those
15 days, so that if major problems arose in any one area the
16 weight of the Department's enforcement capability could be
17 directed in that area whether it was health law,
18 securities law, or whatever it maybe. And there were a
19 number of significant enforcement issues presented to the
20 Department when it received jurisdiction under the
21 Knox-Keene Act in 1975.

22 In keeping with my perception that the
23 thread of history going back to 1930s with managed care
24 had to do primarily with the change of financial
25 incentives and the problems that frequently attended that,
26 perhaps the main provision in the Knox-Keene Act that
27 addresses that is 1367 (g) which requires medical decision
28 making at all levels to be qualified and prohibits

1 interference of medical decision making by fiscal and
2 administrative management.

3 One very brief comment in terms of the
4 historical background by way of summing up. In a sense,
5 we have come full circle on some issues and in particular
6 some of the financial and some of the quality of care
7 problems that the Department observed in the early years
8 with respect to the licensees or I should say applicants
9 for licensure that came from the Knox-Mills Act. In those
10 particular corporations those companies we are now seeing
11 comparable problems on the medical group, the IPA, and the
12 limited licensee level inasmuch as much of the risk that
13 heretofore was assumed and retained by health plans has
14 over a period of years been placed at the medical group or
15 the IPA or limited licensee level which, of course, is
16 consistent with the legislative intent of the Act; but,
17 nevertheless, requires a great deal of sophisticated
18 vigilance to be able to manage.

19 Mr. Chairman, thank you very much.

20 MR. ENTHOVEN: Thank you, Mr. Barnes.

21 Mr. Bishop.

22 MR. BISHOP: Well, Dr. Romero has given me
23 an impossible task of trying to summarize in a meaningful
24 way the Knox-Keene Act. But I think that there's some key
25 points and some themes that are important for this Task
26 Force to understand and to be familiar with.

27 The Act itself is found in the Health and
28 Safety Code; it has over 250 individual sections and it's

1 organized into 19 different articles. It's a pretty long
2 Act. It covers over 200 typewritten pages. I think one
3 of the keys to understanding the Knox-Keene Act generally
4 can be found in one of the very first few sections, which
5 is a statement of legislative intent. And I'm going to
6 focus on just four of the expressed intent of the
7 legislature because they're very important, I think, to
8 the philosophy at least to the Department's regulation and
9 interpretation of the Act.

10 First, the legislature said that one of the
11 purposes of the Act was to assure the continued role of
12 the professional as the determiner of the patient's health
13 care needs. Secondly, they said they wanted to help
14 ensure that the best possible health care be available to
15 the public for the lowest possible cost by transferring,
16 and I think this is rather interesting, by transferring
17 the financial risk of health care from patients to the
18 providers. Thirdly, they wanted to assure the financial
19 stability of plans, and Warren Barnes spoke about some of
20 the early concerns with that. And finally was a broad
21 purpose of assuring that enrollees receive available and
22 accessible health care services rendered in a manner
23 providing for continuity of care.

24 As I said at our first meeting, the Act
25 applies to health care service plans and that's a concept
26 I think some people have in earlier discussions wondered
27 where the line is between insurance and health care
28 service plans. The Act defines a health care service plan

1 as a person who undertakes to arrange for the provision of
2 health care services or to pay for those services in
3 return for prepaid or periodic charge. So one of the keys
4 in that definition is you have a prepayment or periodic
5 charge associated.

6 Then I think the second point is that there
7 is a provision in the Act that says the Act does not apply
8 to a person who has a certificate from the insurance
9 commissioner unless that person provides for health care
10 services either directly or through a contract. So I
11 think that's sort of the second touched on. First is
12 periodic or prepaid charge; the second is the provision of
13 medical services either directly or by contract. That's
14 what makes you subject to the Knox-Keene Act in
15 California.

16 First and foremost the Knox-Keene Act is a
17 licensing statute. You cannot act as a health care
18 service plan in California without a license. In order to
19 get a license from the Department of Corporations you have
20 to file voluminous documents. These documents include
21 your proposed agreements with medical providers, your
22 proposed form of enrollee contracts, your evidences of
23 coverage; you have to demonstrate the -- in the service
24 areas that you propose to go into the capability of your
25 providers and your hospitals. All of this has to be
26 reviewed as well as your financial capability to provide
27 for the services. The application is not something that
28 comes in on a few pages, it comes in by the box load.

1 The other thing about the license is once
2 you get a license from the Department of Corporations, you
3 can't make any material change to your operations without
4 filing a notice of what we call material modification with
5 the Department in getting that notice of material
6 modification approved by the Department. If it's a minor
7 change, you can do it by a planned amendment. If you want
8 to expand your service area, that would require approval
9 by the Department.

10 What I compare this to is if you were an
11 automobile company, it would be like if you want to change
12 your design of your cars you would have to come to the
13 Department of Corporations and get the approval. If you
14 wanted to open a new dealership, you would have to come to
15 the Department of Corporations and get the approval. It
16 is a very high level of scrutiny.

17 The Act itself applies various standards;
18 those standards go to solicitation and advertising, they
19 go to the terms of the planned contracts itself, and they
20 go to more generally the way the plan operates. Warren
21 alluded to some of the problems in some of the early '70s
22 regarding solicitation. The Act has specific prohibitions
23 against deceptive advertising by plan or plan solicitors.
24 The Act requires specific disclosure in terms of evidences
25 of coverage, and there are numerous provisions in the Act
26 that go to very specific topics, like there's specific
27 requirements regarding arbitration provisions or processes
28 for denying services. Also there's disclosure provisions

1 relating to how the plan operates, its grievance
2 processes, and more recently a disclosure requirement
3 about the Department's toll free hot line number. There
4 are numerous kinds of specific disclosures that have to be
5 made. In addition to the soliciting -- oh, one more point
6 on the advertising. Advertising by plans has to be filed
7 with the Department of Corporations.

8 In addition to the advertising solicitation
9 standards, there are specific contract standards. The
10 contract that the plan enters into with the purchaser or
11 the enrollee to provide the services. There are just
12 pages and pages of contract standards that are set forth;
13 there's Article 3.1 which deals with numerous requirements
14 that relate to small employer group plan contracts;
15 there's an Article 3.5 of the Act which deals specifically
16 with Medicare supplement contracts.

17 In addition, there's a general provision in
18 the Act which requires that all contracts with enrollees
19 as well as all contracts with the providers must be fair
20 and reasonable and consistent with the provisions of the
21 Knox-Keene Act.

22 Thirdly, in addition to the advertising in
23 the specific contract requirements, there are specific
24 standards for the operations of the plan and these --
25 there's some very general standards which I think
26 collectively represent the heart and soul of the
27 Knox-Keene Act and one in particular I think that is
28 fundamental. I will hit on a few of them.

1 **First, all facility providers and equipment**
2 **that the plan uses must be dually licensed in California.**
3 **Second, all services must be made readily available at**
4 **reasonable times to enrollees. Thirdly, the plan must be**
5 **able to demonstrate to the Department that it has the**
6 **organizational and administrative capacity to provide the**
7 **services that it is contracting to perform. Fourthly --**
8 **and this one I think is really the most fundamental and in**
9 **terms of the philosophy of the Act -- is that the plan**
10 **must be able to demonstrate that medical decisions are**
11 **rendered by qualified medical providers unhindered by**
12 **fiscal and administrative concerns.**

13 **In addition to these more general**
14 **requirements, the Act is filled with a lot of very, very**
15 **detailed requirements relating to all kinds of specific**
16 **situations. In many cases, I believe the specific**
17 **requirements are basically footnotes to the more general**
18 **requirement. For example, there's a provision requiring**
19 **comprehensive preventive care for children. I think while**
20 **that's in the Act, I think it's also part of the more**
21 **general requirement that plans provide basic health care**
22 **services. There's specific requirements for coverage of**
23 **osteoporosis, there's specific requirements for prosthetic**
24 **devices or reconstructive surgery regarding mastectomies.**
25 **There are a whole lot more of these specific requirements**
26 **that run for pages and pages in the Act. But what I want**
27 **-- I think it's important to understand that there's a lot**
28 **in there in terms of specificity.**

1 I think the Act in addition to being a
2 licensing Act is one that provides for continuous
3 oversight of the plans. The plans are subject to periodic
4 medical surveys which are on-site surveys; those are
5 required to be conducted every three years. The plans are
6 also subject to periodic financial examinations which are
7 required to be done every five years. So there's more or
8 less constant contact.

9 In addition to these periodic surveys, there
10 are follow-up surveys and what we call non-routine
11 surveys, which are what the Department conducts when they
12 become aware of a potential problem. They may go in and
13 do a non-routine, on-site investigation or survey
14 investigation or survey of the plan or specific aspect
15 plan of the plan's operations.

16 Finally, the Act provides for broad
17 enforcement powers. We have the authority, the Department
18 of Corporations, to issue administrative cease and desist
19 orders. We have the authority to institute civil
20 injunctive actions; we have the authority to seek
21 appointment of a receiver; we have the authority to seize
22 the business; we have the authority to seize or to freeze
23 new enrollment; and we have the authority to issue civil
24 penalties.

25 The thought that I would like you to be left
26 with is that there is a lot in the Act now both in terms
27 of specificity but also some very important and broad
28 general principals both in the legislative intent and in

1 these general standards that apply to plan operations.
2 It's a very comprehensive Act. It's not necessarily the
3 best drafted act because it's been added to, and sort of
4 like a house that's built without a plan, but there's a
5 lot there and I really encourage people who are
6 considering Knox-Keene Act regulation become familiar with
7 the way the Act operates, the philosophy of the Act, what
8 is required of plans now.

9 MR. ENTHOVEN: Thank you very much. We did
10 ask that a copy of the Knox-Keene Act be sent to every
11 member of the Task Force and I trust you all have it and
12 are working your way through it diligently.

13 Are there questions from the Task Force?

14 MR. ZAREMBERG: I think the charge of the
15 commission was to look at who should provide oversight
16 governs, not necessarily whether we should amend the
17 Knox-Keene Act, maybe Commissioner could talk to us and
18 discuss with us the implementation of the Act. How you
19 see you do your job? For example, on the issue of medical
20 decisions is there -- how do you process that or are there
21 issues there? I mean there's things in the Act but how do
22 you implement those? And I guess finally you've received
23 I think a large budget augmentation, how do you see that
24 being utilized and how would that be addressed in the
25 future and what would that be used for? I think that's
26 important to our charge here.

27 MR. BISHOP: I would characterize Knox-Keene
28 Act as particularly with a plan of any size of almost

1 continuous contact between the plan and the Department and
2 the contact comes about in a variety of different ways.

3 As I said the Act requires that any material
4 change in the operations. It's rather extraordinary if
5 you want to expand your business normally you don't go to
6 the State and get permission. If you want to change a
7 contract term normally you don't file your contracts with
8 the State. So there's this avenue of material
9 modification plan amendment contract process in
10 advertising that we get filings all the time.

11 The medical survey process is a point of
12 constant contact as is the financial examination and it's
13 the medical survey is just a flavor of it. There's an
14 on-site portion, but once that is done then the
15 preliminary report is delivered to the plan and there's --
16 the plan has a chance to respond and that is a process of
17 interaction.

18 There's also the complaint process. We have
19 had for some time in consumer services unit starting in
20 October of '95 we inaugurated the 1-800 number. So that
21 is a point in which we're handling individual complaints
22 that come in to the Department. When we get a complaint
23 we contact the plan to get both medical information, if
24 medical issues are involved, and the plan's at least
25 position on the complainant. Those complaints then they
26 go through their process but they also dove tail into our
27 on-site survey processor point of data for that process or
28 may be flipped over into an enforcement proceeding.

1 That's the other area of contact is through
2 our enforcement processes, we may be doing an
3 investigation or actually engaged in litigation with the
4 plan.

5 In terms of the augmentation --

6 MR. HAUCK: Keith, before you go on with
7 that, before you got the augmentation, given the extent of
8 the Department's potential contact with the plans, were
9 you actually able to perform on the mandate of the law?

10 MR. BISHOP: We were basically in a triage
11 situation in terms of trying to fight the hottest fires
12 and the augmentation was something we began looking at
13 last December; Gary Haggin (phonetic) is the assistant
14 commissioner for the health plan division. What I wanted
15 to have done was basically a performance review. Look at
16 all sectors of our activities, what we required to do
17 statutorily, whether we were -- what our backlog was,
18 whether we were meeting our statutory performance
19 standards or an internal performance standard, and if it
20 weren't what it would take to get there. So that was the
21 genesis of the augmentation that we requested. The
22 augmentation --

23 MR. HAUCK: The answer was you weren't
24 sufficient?

25 MR. BISHOP: In many areas we were behind.

26 MR. ENTHOVEN: Jeanne.

27 MS. FINBERG: I wonder if you can comment on
28 the separation of the regulation of the PPOs and then also

1 on the overlap in your oversight responsibilities and
2 quality measurement with the Department of Health
3 Services. So in other words the Department of Insurance's
4 part and the Department of Health Services' part.

5 MR. BISHOP: I'll give you a general answer
6 and Warren is the master of this issue but basically the
7 fundamental dividing line, as I said, there's two parts to
8 being a health plan prepaid or periodic charge, and the
9 other is basically the provision of services. And
10 normally a PPO, which would not be regulated by us, would
11 fail one of those two tests, usually it's the test of the
12 prepaid or periodic charge.

13 MS. FINBERG: Maybe I should clarify my
14 question. I didn't really mean what it is now because I
15 know what it is but whether you think it should stay like
16 that if it isn't working with those lines. Because as you
17 know there's several proposals to change that and I
18 wondered what your view of those changes would be.

19 MR. BISHOP: I view that as a fundamental
20 difference between insurance and health care service plans
21 and basically the difference is within an insurance
22 company basically they're indemnifying you against a loss
23 that you may incur. In the case of health care it's not a
24 health care cost. You don't hold the insurance company
25 accountable under indemnity insurance for the providers --
26 the job the provider does. The old system, if you had
27 health insurance, you would choose your doctor, if your
28 doctor did a bad job you would go after them for

1 malpractice.

2 The nature of the obligation with the health
3 care service plan in my mind is fundamentally different
4 which is that they both take the risk of health care costs
5 but they also undertake the obligation to provide or
6 arrange for the provision of health care services. And so
7 insurance regulation is directed mainly at ensuring that
8 one the insurance companies have the financial capability
9 to meet the obligations; and, secondly, that they're
10 honoring their contracts.

11 Our job is a lot more complicated because
12 the contract performance in insurance is paying the money.
13 Our job is that to ensure that they're providing the
14 quality of care and the services that they are obligated
15 to provide. So it's a very different, I think, kind of
16 regulation. It's much heavier regulation under the
17 Knox-Keene Act than under the Insurance Code because there
18 are a lot of things we look at that there would be no
19 reason to look at in a pure indemnity insurance
20 environment.

21 MS. FINBERG: So you see a fine line between
22 the provider organizations and the HMOs, and if you had,
23 for example, a health service plan with a point of service
24 option so you're getting in to some sort of mixed animal
25 you still see it would be appropriate to have them
26 regulated separately?

27 MR. BISHOP: I think that, you know,
28 fundamentally the health care service plans they're

1 offering a different product, which is a service, it's not
2 a promise to pay money and that's what really
3 distinguishes the Knox-Keene Act regulation.

4 MS. FINBERG: And then the quality side, the
5 other part of the question was the oversight with regard
6 to quality that your agency has and shares at least for
7 some plans with the Department of Health Services.

8 MR. BISHOP: We do share -- there is an
9 overlap. The Department of Health Services contracts on
10 behalf of the Medi-Cal beneficiaries a plan that we
11 license and are responsible for may have a lot bigger
12 enrollee base than the medical beneficiaries. So our
13 responsibility is broader to the extent that there are
14 commercial enrollees. In most of these plans there are,
15 and we would look at protecting all the enrollees of the
16 plan making sure the plan meets all the obligations of the
17 Knox-Keene Act where -- and I will let Kim Belshe' speak
18 for her regulations, but at least my understanding of it
19 is that they're primarily looking to see that the Medi-Cal
20 regulations and statutes are complied with for the
21 protection of the Medi-Cal beneficiaries.

22 MR. ENTHOVEN: Mark Hiepler and then John.

23 MR. HIEPLER: Question to both Mr. Barnes
24 and Mr. Bishop.

25 I represent a lot of patients who are denied
26 care they believe they're entitled to as well as
27 physicians and groups on the business issues whether or
28 not they're reimbursed, and from our perspective, the

1 patient perspective, they see their HMO is the local
2 medical group, the local management company, that agrees
3 or disagrees with their doctor's decisions and judgments.
4 And more and more it seems as if the HMOs are delegating
5 their duties and responsibilities to these IPAs as
6 Mr. Barnes spoke of. What existing oversight is there,
7 other than through the top of the HMO, to make sure they
8 have a contract in place with an IPA to actually regulate
9 who really is doing the bulk of managed care right now the
10 IPAs, the medical groups. Is there any angle right now
11 existing to really make sure that those IPAs are
12 fulfilling the responsibilities of the Knox-Keene Act to
13 make sure that finances aren't the first issue before
14 health care and rather the other way around?

15 MR. BISHOP: I guess there is at least two
16 answers to that. From our perspective we hold the plan,
17 the plan is our licensees and we hold the plan accountable
18 whether they choose to use contractors or not they're
19 accountable for the performance and for complying with the
20 Act. And that was illustrated I think best in the case of
21 Carla Christie (phonetic) which is where we find take care
22 of \$500,000. Initially the decision was made at the group
23 level and the plan at least wanted to defend itself by
24 saying that's not us. But we hold the plan accountable
25 for the act, in compliance with the Act.

26 Secondly, there has been at some of these
27 groups and organizations have gotten bigger. We have
28 issued limited licenses to some of them and once they come

1 under our license then they are subject to the provisions
2 of the Act and to enforcement by us.

3 Warren, is there anything you would --

4 MR. BARNES: I might augment briefly that
5 you're quite correct that the action today from the
6 consumer perspective and certainly the consumer's
7 expectations are focused more on the medical group or IPA
8 than the health plan, and research may or may not show
9 that the real critical variable is the fact that the
10 medical group and in specific the primary care physician,
11 assuming the plan uses a gatekeeper model as the vast
12 majority do.

13 Commissioner Bishop said that the plans are
14 responsible. They're responsible in two primarily ways.
15 First of all is to assure that the medical group or IPA
16 has the fiscal and administrative capacity to do the job
17 that the Department requires the plan contract or provider
18 contract between the plan and provider group to obligate
19 the provider group to do. Plan has complete oversight on
20 that side of it. Also as Commissioner Bishop indicated
21 complete oversight on quality of care defined broadly to
22 include everything that a consumer would need insofar as
23 meeting completely the requirement that medically
24 necessary services be provided when necessary not when the
25 plan would like to balance that out against other
26 considerations.

27 Although, again, the question shows the
28 awareness that balancing out medical necessity against

1 other considerations more frequently now is happening at
2 the medical group or IPA level inasmuch as the vast
3 majority of them are capitated at least for physician and
4 related services, the limited licenses that Commissioner
5 Bishop alluded to are typically sought and provided once
6 demonstration of compliance has occurred. In a situation
7 where either a management company rather than the
8 medical group itself in fact is operating as a plan within
9 the definition of 1345 (f) or where the medical group or
10 IPA is responsible not only for professional but for also
11 institutional services or vice versa. That is where the
12 action is and it's the interplay, the tension between
13 financial incentives of all types and the market moving
14 rapidly therefore financial incentives are evolving
15 rapidly. It's the tension between the financial
16 incentives on the one hand and quality of care, the
17 Hippocratic Oath assuring that services are provided when
18 they're need and that they're medically appropriate enough
19 to the standard of care. That is where the action is
20 today. It's much more finely tuned, it's much more
21 complex now than it used to be. But in very generic terms
22 that's where the action has always been although
23 historically it's been much less action there.

24 MR. HIEPLER: You guys sit in a very unique
25 position. Do you feel that there should be more direct
26 regulation, I guess for lack of a better word, of the IPA
27 level or do you feel that you can control them
28 significantly by looking at the big player, the HMO, and

1 having them work down?

2 **MR. BARNES:** With the promise of staffing
3 sufficient to bring us to what I would consider to be an
4 adequate level, there is I think a very high likelihood.
5 I have the expectation and I believe it's realistic that
6 under the existing regulatory scheme we will be able to
7 provide that. That presupposes two invaluable sources of
8 current information that Commissioner Bishop alluded to
9 earlier and one is consumer complaints.

10 The more we get the 800 number in the public
11 mind and the more we hear from consumers the more we're
12 able to identify where there are problems. And the very
13 same thing is true of providers, even though the
14 Department has no authority to require proper resolution
15 of provider complaints. Nevertheless, it is true to the
16 extent that providers can be induced to provide
17 information regarding a problem. We do get information in
18 plain manila envelopes. It sometimes helps the Department
19 because it helps us to know where to look.

20 The problem with that is frequently
21 consumers may lack the sophistication to define the
22 problem to understand where they are, how they arose, and
23 what can be done with them. On the consumer side -- and
24 frequently the problem with that on the provider side is
25 now that the providers are largely being incentivized to
26 have what some consumer advocates consider to be an
27 inherent conflict -- medical necessity on the hand verses
28 financial incentives not to provide care on the other

1 hand. It isn't normal to expect physicians or other
2 health care providers to relate to that ethical dilemma by
3 corresponding with the regulator.

4 MR. ZATKIN: Now --

5 MR. ENTHOVEN: I have a list I'll you put on
6 the list. We've got John Perez, Bruce Spurlock, Peter
7 Lee, Bernard Alpert, and Rodrigues-Trias and I'm seeing
8 there are time horizons so I'll put on the list and we'll
9 cap the list here, okay.

10 MR. PEREZ: I wanted to get back to Mr.
11 Hauck's questions. What deficiencies specifically did you
12 identify prior to requesting the augmentation?

13 MR. BISHOP: They were specifically
14 identified in the augmentation, but they ranged from
15 timely processing of the notices in the June modification.
16 Under the statute, we're supposed to process those within
17 20 days and we weren't meeting that goal. It was just a
18 list of many of the things like that that the consumer
19 services unit -- one of the things that I've been very
20 focused on in the last year is speeding up the time of
21 response to consumer complaints and what we found is that
22 we had, at least a year ago when I came on board, a very
23 large lack of medical consultants and we've increased in
24 the last year within existing resources the number of
25 medical consultants by 700 percent available to the
26 Department. We need more both from -- the just having the
27 number of consultants but also we have to cover a range of
28 specialists. We can't have one doctor. We need

1 **ophthalmologists, dentists, OB/GYN, internist --**

2 **MR. HAUCK: What are the numbers?**

3 **MR. BISHOP: Seven to over 50.**

4 **MR. ENTHOVEN: Of medical consultants?**

5 **MR. BISHOP: Yeah.**

6 **MR. BARNES: Physician.**

7 **MR. PEREZ. How far are you now from being**
8 **closer to what you think is optimal running in terms of**
9 **making some of these changes and what are some of the**
10 **financial constraints that may be impeding some of that**
11 **progress?**

12 **MR. BISHOP: We don't have the augmentation**
13 **yet, so we have no -- people have been hearing about the**
14 **augmentation assuming that we actually have the money. We**
15 **don't have the money; the budget has not passed yet. When**
16 **it is passed, then we will get the money and we will have**
17 **to staff up accordingly. So right now we're operating**
18 **under the budget that I got a year ago; we'll do that**
19 **until June 30th or until there's a new budget.**

20 **MR. PEREZ: But given the augmentation that**
21 **you expect, how close do you expect to be within a years'**
22 **time frame?**

23 **MR. BISHOP: Based on our performance that's**
24 **what we think we need. And we did a performance analysis**
25 **of all areas including the enforcement area and in our**
26 **budget augmentation request we requested a doubling of our**
27 **enforcement council.**

28 **MR. ENTHOVEN: Thank you.**

1 **Bruce.**

2 **DR. SPURLOCK:** I want to go back to what
3 Mr. Zaremborg was addressing earlier on when he talked
4 about financial influence on the decision-making
5 process --

6 **THE REPORTER:** Excuse me, could you slow
7 down a little, please.

8 **DR. SPURLOCK:** Okay. We all understand the
9 complexity of the physician compensation issue and how
10 difficult that is. I'm curious what activities and what
11 methods -- I'll get that out one of these times -- that
12 you used to deal with that issue of undue financial
13 pressure on the decision maker and in this world of
14 outcome what kind of outcome can be measured? We know
15 HICFA is now asking medical groups to display their
16 compensation and bonus processes. Is that the type of
17 thing that you do or how do you look at that and what are
18 the outcomes of those ethics?

19 **MR. BISHOP:** One of the frustrations for me
20 and the whole managed care field is there's sort of a
21 historical amnesia that the debate seems to start with the
22 advent of managed care and looks at everything as if there
23 was no history. And I think the history is that there
24 have always have been conflict of interests inherent with
25 physicians. There were different conflicts of interests
26 but they existed and they existed under the old fee for
27 service because there it was clearly an incentive or
28 potential incentive for the physician; the more he did the

1 more he billed. And there was also financial incentives
2 related to referrals to medical clinics and drug labs and
3 things like that that led to federal legislation with very
4 severe criminal sanctions. Pete Stark (phonetic) authored
5 that and there was quite a backlash about those
6 incentives.

7 So we're not operating in an environment in
8 which there won't be incentives. Every system will have
9 economic incentive, and I think that's important to
10 remember as we look at this it's not just to look at
11 managed care regulations in isolation as if there was no
12 history. I don't know that there's a system that won't
13 put the professional and everybody in the system, you
14 know, totally free of economic incentives.

15 We do -- there are specific provisions in
16 the Knox-Keene Act that prohibit, you know, payments for
17 denying care, and I can let Warren get into the specifics
18 of those if we can talk about that.

19 MR. BARNES: The failure to provide
20 medically necessary care, as we all know, is prohibited on
21 the part of a plan and consequently on the part of the
22 contracting providers. I think the Department is acutely
23 aware of the need for fine tuning in the tension between
24 fiscal incentives and quality of care and measurement of
25 quality of care and we're doing this in part through
26 upgrading the caliber of the people who are doing our
27 work.

28 For example, we now have a doctor of nursing

1 who is the person primarily responsible for handling
2 merchant complaints who has a greater ability to spot and
3 deal with those issues than would, for example, a regular
4 R.N. By contrast, at the same time incentives are very
5 rapidly evolving. Today's incentives may or may not be
6 tomorrow's incentives. It's almost that rapid.

7 One of the geniuses of AB 138 when it was
8 enacted in 1975 was to provide, for the most part, general
9 regulatory provisions that afforded the regulator a great
10 deal of flexibility to enable plans to keep up with the
11 marketplace but at the same time provide necessary
12 consumer protections, and the action now is with financial
13 incentives and quality of care, measurement of quality
14 care. One issue, obviously, is a sense the vast majority
15 of providers are now capitated the amount of capitation
16 payments. All provider compensation by law under the
17 Knox-Keene Act capitation or otherwise incentives or not
18 is all confidential. I have seen some eyebrows raised on
19 the staff level of some of the capitation payment.
20 Services have to be provided. Providers have to be
21 compensated. It's very difficult; it takes the wisdom of
22 Job to regulate that situation the way which doesn't
23 impede legitimate business at the same time which allows
24 providers to receive what they need to receive so that
25 consumers can receive what they need to receive.

26 DR. SPURLOCK: So you see all the capitation
27 contracts, do you, is that what you stated?

28 MR. BARNES: We see all compensation

1 arrangements with physicians who contract with plans or
2 medical groups or IPA who contract with the plans. We may
3 or may not see the financial arrangements that a
4 particular medical group or IPA has with a particular
5 physician member of that group or IPA.

6 MR. ENTHOVEN: Let me butt in for a minute.
7 This is an excellent discussion and I hate to curtail it
8 but I also am concerned about the clock so I would like to
9 see if we can move through the others very quickly. There
10 are very interesting points.

11 Peter.

12 MR. LEE: Two questions. One is I want to
13 come back to Jeanne's question, the question about the
14 audits, but I understand the different functions of the
15 DHS and DOC, the question was specifically in terms of
16 having multiple similar functions happening like medical
17 audits. I would like to know what the Department's doing
18 currently in terms of streamlining auditing of health
19 plans, medical groups between not DHS but also private
20 sector, that's one.

21 The other question is specifically related
22 to complaint data, are you currently collecting or
23 tracking complaint data by medical groups and to your
24 knowledge is that one of the major things we need to be
25 looking at is those frontline providers. Because I know
26 it's not reflected in the report here, the new report, but
27 are you collecting and analyzing data by provider group?

28 MR. BARNES: In terms of in coordination

1 with DHS and others on quality assurance, the private
2 organizations like Nick (phonetic) that are reviewing for
3 quality, we take that into consideration. But our reviews
4 are in many ways different and I think in some ways at
5 least certainly preferable from the consumer perspective
6 we go to provider offices; we review consumer charts. We
7 look in those areas where our experience tells our
8 professionals there are most likely to be problems, but we
9 take all of that into consideration. We obviously
10 contract with highly qualified professionals to conduct
11 all of our surveys either on an out-source basis, as is in
12 the case with full service, or to augment our full-time
13 staff with regard to other plans.

14 The evolution of a corporation with DHS has
15 occurred over a period of years. DHS tends to track the
16 service, the services that are received for the dollars
17 that are paid as a generalization, and the Department of
18 Corporations has more of a systems wide audit based on
19 assuring compliance with the system to primarily the
20 Knox-Keene Act but at the same time, as I indicated,
21 delving into where problems may be found. Over a period
22 years we've done some things with DHS, they have done some
23 things for us, we've done some things for them; sometimes
24 we've gone out together. Sometimes plans have squealed,
25 there are too many people, get the hell -- I'm sorry, get
26 out of here, there were too many of you. And sometimes we
27 adopt their report. But in general my perception is that
28 the current relationship with DHS is quite cordial. It's

1 impossible to cooperate with anyone in a basis that is
2 fully satisfactory to everyone in the industry.

3 MR. LEE: Next question on medical groups
4 and complaint data.

5 THE REPORTER: Excuse me, my machine has
6 been blinking at me for an hour, I'm going to run out on
7 my battery. Can we take five minutes, please.

8 MR. ENTHOVEN: Sure. Five minute reporter
9 break.

10 (Recess.)

11 MR. ENTHOVEN: The next question will be
12 asked by Dr. Helen Rodrigues-Trias.

13 MR. LEE: I object, your Honor.

14 MR. ENTHOVEN: Oh, sorry.

15 MR. LEE: I had a follow-up question that
16 was about to be respond to.

17 MR. ENTHOVEN: Excuse me, I'm sorry.

18 MR. LEE: You still get to go next, I was
19 not objecting to your perspective.

20 (Whereupon numerous council members spoke at
21 once.)

22 MR. BARNES: The chairman has been inducing
23 me to be brief.

24 The Department is very cognizant of which
25 medical groups and which physicians account for
26 complaints, but the answer to your question is no we do
27 not compile that data. That -- compiling the data in a
28 formal way we do not do, but we are aware of it with our

1 complaint process, and we are cognizant of it and we
2 combine the complaint process merge it into some extent
3 the medical survey process to accommodate those kinds of
4 issues. Actually collecting the data in a formal way and
5 a statistical way is an example of scores of things that
6 the Department would like to be able to do which it hasn't
7 had the resources historically to do.

8 MR. LEE: Which you would be able to do with
9 your augmentation?

10 MR. BARNES: I would anticipate that this
11 would be among those things we would be able to do, but
12 please bear in mind it would be confidential information.
13 It would not be anything we would be in a position to
14 publish under current law.

15 MR. ENTHOVEN: Helen.

16 DR. RODRIGUES-TRIAS: We received some
17 information on the medical managed care quality initiative
18 which I understand you're a part of the group that's
19 working on that, and I wandered if you could comment on
20 what implications this may have in terms of the cost of
21 doing the quality insurance vis-a-vis in order for the
22 system from getting -- but also into moving into more
23 outcomes type evaluation.

24 MR. BISHOP: In terms of quality care I
25 think you raised a very good point which is at least the
26 way I think we should -- the debate has been processes
27 outcome. The way I see it is quality care should be a
28 function of both the procedures and the cost and in a

1 very -- I also think it should not be a static measure
2 with where you take a snapshot at one point in time. A
3 person's life is like a movie, it continues. You just
4 don't have a procedure and that's the end of everything.
5 I think we should ultimately be looking at a definition of
6 quality of care that is a function of the change in health
7 status which is the change in cost, the expenditures, and
8 that is a view that I would encourage the Task Force to
9 put back in the cost element of this function. And it's
10 actually, you know, in the -- when I was talking about the
11 intent of the act they were talking about assuring the
12 best possible health care at the lowest possible cost and
13 I think that captures what I think is really important.

14 MR. ENTHOVEN: Brief comment by Dr. Alpert.

15 DR. ALPERT: I want to thank Mr. Bishop and
16 Mr. Barnes for clarifying for the first time for me where
17 the root of the entire problem is that we've been
18 grappling here, i.e., the incentives, the quality, the
19 cost and so forth. I didn't realize the root was right in
20 this act codified.

21 You started by quoting, picking four points
22 and then elaborated, I think it was four others, and the
23 one you just talked about, again, is helping to assure the
24 best possible health care cost for public at the lowest
25 possible cost by transferring financial risk from patients
26 to providers as opposed to the next point which says an
27 oversight on quality of care, care must be given by
28 qualified medical providers unhindered by fiscal concerns.

1 Those are incompatible statements both
2 contained in the Act, and to me codify the root of our
3 entire problem and perhaps we should point that out in a
4 summary as we begin to say wherever we are going to go.

5 MR. BISHOP: I would say again I think those
6 are both very important that's why I mentioned them. One
7 is the intent of the legislature; the other is the actual
8 legal standards the plans have to meet.

9 I don't think any system will ever be free
10 of economic incentives on providers or the plans or any
11 other participant on the health care delivery system.
12 There were will be incentives. The assumption with regard
13 to the discussion this morning is there's an incentive to
14 provide less care. There are arguments that there are
15 incentives to provide preventive care and minimize cost to
16 the plan by reducing the -- by forestalling big plan cost
17 by low cost preventive measures.

18 So although the discussion has been sort of
19 this morning that there's always the incentive to provide
20 less, there may actually be incentives within this system
21 to provide preventive and other care which lowers the cost
22 of health care for the clients.

23 MR. ENTHOVEN: It's a good question we need
24 to discuss more. On the face of it there's quite a bit,
25 so thank you for raising it, but let's be sure to revisit
26 that.

27 MR. HARTSHORN: I wanted to respond and we
28 can perhaps go up another level because the HMO Act, the

1 federal act in 1975 has -- I don't think it's exactly the
2 same but that started the process for lots of states to
3 start changing their regulatory process for HMOs. So we
4 have to look at also -- I mean not that it's our
5 responsibility but to start at a federal level as well.

6 MR. ZAREMBERG: I think it's important. I
7 think we should discuss this further and I appreciate what
8 Dr. Alpert said, but I think there's another way of
9 looking at it rather than saying they're inconsistent and
10 one is a statement and one is a qualification of that
11 statement and one is a goal and it's qualified. How you
12 do it and ensure that you don't inhibit your ability to
13 medical decisions or are inhibited by financial incentives
14 or in making sure more people have health care I don't
15 think is inconsistent with that qualification. So I think
16 it's worthy of further discussion but I think it's
17 important to point that out that it may be apparently
18 inconsistent but I'm not convinced it is.

19 MR. ENTHOVEN: Well, and we have to
20 recognize the inevitability of cost containment, that is
21 we can't go up to 20 or 30 percent of the GNP spent on
22 health care. So somewhere, somehow people are going to
23 have to make value for money tradeoffs, and it can be a
24 real problem as our society comes to terms with that and
25 recognizes it.

26 I think we're going to have to stop now and
27 move to the next. Thank you very much.

28 MS. SINGH: Steve Zatzkin --

1 **MR. ZATKIN:** I told Allan my question
2 already and it had been asked by Bruce on financial.

3 **MR. ENTHOVEN:** Now we're going to have Ellen
4 Severoni is going to lead the discussion on consumer
5 information and involvement. She is the executive
6 director of California Health Decisions and then she'll be
7 followed by Ms. Jeanne Finberg from the Consumers Union
8 who will comment on that and put forward some of her ideas
9 on consumer involvement and information.

10 We'll start with Ellen up here.

11 **MS. SEVERONI:** We're going to be using
12 slides so they'll be projecting right up here for you.
13 I've heard enough jabs about the fact that these
14 definitely look like they're from Southern California.
15 Spain is the name of the program on the computer so that's
16 why.

17 Anyway, thank you very much. I'm going to
18 move as quickly as I can through three different points
19 that all evolve around in involving the public around
20 health care choices. Each of you has a packet at your
21 place that has copies of these slides which will allow me
22 to move through more quickly because I know you'll be able
23 to look back and reflect at a later point.

24 I'm going to very briefly give you a bit of
25 sense about California Health Decisions and our work
26 involving the public and some of the starting points for
27 the public when we talk about health care. Then I am
28 going to talk briefly about the Medi-Cal member advisory

1 committee that CHD organized for the CalOPTIMA program in
2 Orange, and at that point I will introduce a guest that we
3 have, Estella Martinez, from the CalOPTIMA program in
4 Orange. She is the staff person responsible for the work
5 of that committee. It has been two years since I have
6 been there, so she can tell us how this
7 consumer-involvement model is working.

8 And then thirdly, I will be discussing what
9 are called consumer feedback loops which are very recent
10 projects that CHD has created with the help of several
11 health plans, large medical groups and large employers in
12 this state that bring enrollees directly to the table in
13 determining how the system will recreate itself and
14 improve itself.

15 So we have been around since 1985 and our
16 mission has never changed. We are committed to educating
17 and involving the public in issues relevant to individual
18 and societal health choices; to assure that community
19 values are incorporated into health policy.

20 Since our beginnings over 80,000
21 Californians have participated in our activities and
22 programs. Most of those people have sat in town hall
23 meetings, like the one we are sitting in today, as a way
24 of participating in small group meetings as well as in
25 focus group research.

26 I would like to say within the first ten
27 years of our existence, we would point out that there are
28 five areas that we consistently find that experts like

1 yourselves and the public perceive in very different ways;
2 first would be cost. Most ordinary people think about
3 what they spend out of pocket, so every time an article
4 appears talking about how cost of health care
5 has gone down as a result of managed care, most people are
6 thinking about the fact they're paying more now in
7 co-pays, being asked to make more tradeoffs. So we don't
8 start the same place.

9 In terms of coverage, people really don't
10 clearly understand who is and who is not covered and we
11 all know that how we do that in our society does drive the
12 costs of care.

13 In the next area waste, fraud, and abuse.
14 The public thinks this is the cause of rising cost and why
15 they're being asked to make more difficult tradeoffs.
16 Just thinking last week, what were headlines, 23 billion
17 dollars in inappropriate payments in the Medicare program.
18 For whatever reason these are issues that continue to
19 plague us.

20 The next two areas both technology and
21 aging. Those are areas where there's very little
22 understanding at all in terms of how technology, for
23 instance, drives the cost of care and the aggregate.
24 People see that more clearly, more duplication part of the
25 greed issue. Most people tell me Ellen it's Economics
26 101. I bought a VCR 15 years ago it cost well over
27 \$1,000. Buy one today it's several hundred dollars.
28 Technology makes things cheaper.

1 In terms of aging, this does not seem to be
2 lost on people but in our experience at CHD resisted.
3 People who have self-selected, and most of them have, come
4 out to our meetings are 45 or older and it's very
5 difficult to get them to think about their parents and
6 others who are looking at having maybe more limited
7 choices and thinking about needing the tradeoff; that's
8 just a starting point.

9 We've found you can either throw your arms
10 up and say there's no way to close those gaps with
11 education, or you can change the way you hold
12 conversations with the public to be focused in on values.
13 And over the years of our work we have found that these
14 seven values, and I have mentioned them in previous
15 meetings, are used over and over again by the public when
16 they think about and talk about health care choices and
17 making tradeoffs. And I would suggest that these are the
18 kinds of values that most of our organizations pose as
19 important to us when we think about how we are going to
20 provide service to the public. So I think there's quite a
21 large common ground here.

22 Values drive decisions and I'm going to
23 focus today mostly on the first folic and last folic.
24 First in terms of defining quality, which is something I
25 believe the experts and the public must do together if in
26 the coming decades we are going to be able to agree upon
27 what quality is and have consumers be able to use that as
28 a tool to move from provider to provider and from plan to

1 plan, and I think maybe we better, instead of having
2 someone coming from the foundation for accountability back
3 to talk with us about the work they're doing in putting
4 quality information into the hands of consumers.

5 Certainly in choosing a plan or a physician
6 values are important in deciding on treatment options,
7 considering end-of-life choices. Just as an aside we've
8 done workshops for 50,000 people here in California on how
9 to complete advanced directives. In an evaluation we
10 found that two-thirds of the people who come to our
11 workshops go on to complete advanced directives. It's
12 very a high record, and again we use values as opposed to
13 talking about treatment options.

14 And then on values to evaluate health
15 reform, and that's going to move me to the very first
16 consumer involvement model that I would like to talk with
17 you about.

18 One of CHD's concerns was that mostly white
19 women 45 or older and with middle or upper-middle incomes
20 was most of those 80,000 people were coming out to our
21 programs. We decided in 1993, when it became clear that
22 the Department of Health Services and the State of
23 California was going to be moving more Medicaid members
24 into managed care, CHD decided we were going to go out and
25 talk to Medi-Cal members. And especially with our offices
26 there in Orange, it was important Orange County was going
27 to develop a county organized health system for just under
28 300,000 members.

1 Our goal was to develop a replicable model
2 by which the Medi-Cal members, the beneficiaries values
3 and needs could be incorporated through their direct
4 participation into all phases of local organized Medicaid
5 manage care systems. Forgive me, I do this slide on a
6 national, these programs nationally so I switch back and
7 forth between Medicaid and Medi-Cal slides often.

8 Now when I showed you those set -- that set
9 of values, you have in your packets an executive summary
10 of some focus group research we did in 1993 with Medi-Cal
11 beneficiaries. I would like to encourage you to either
12 visit our web site to download this 50-page document of
13 that research or certainly contact CHD and we'll mail you
14 the full report, which I have in my hands here. But just
15 to give you a sense that when we moved to working more
16 closely with Medicaid population, what we found is people
17 use the same values, it doesn't matter who your insurance
18 plan is, you're use the same values to make decisions but
19 the priorities are different. And this population focused
20 much more on the issues of being treated fairly and with
21 dignity and respect. The cross section looking much more
22 at affordability and personal responsibility with both
23 groups very concerned about quality and accountability.

24 When I use the word accountability, just to
25 generalize, we're talking about where people are able
26 within the system to find that person, that body who can
27 help them either navigate their way through or resolve a
28 problem. So the difference between person and

1 responsibility and accountability is the accountability
2 value is very clearly related to systems.

3 I was a member of the board of supervisors
4 task force on health care and when the county decided it
5 was going to set up a county organized health system for
6 our 300,000 beneficiaries, I was fortunate enough to have
7 the board appoint me to chair a member advisory committee.
8 They asked Dr. Camerman (phonetic), the president of the
9 Medical Association, to chair the provider advisory
10 committee and the county health care agency served as the
11 government body that help spearhead the move.

12 I've come back to this point many, many
13 times. The member advisory committee existed before
14 CalOPTIMA, before the board of directors, before the CEO
15 existed. And that had a lot to do with how integrated
16 this member advisory committee is. We used the research
17 that I have discussed briefly to ground the member
18 advisory committee in its policies and practices. So we
19 used the beneficiary's research.

20 I have never been on the Medicaid program so
21 feeling that I could chair a committee like this would
22 have been very difficult if we hadn't talked specifically
23 with beneficiaries. Although I will share with you that I
24 have two sisters on the East Coast who have both used this
25 program to provide health care for them and their
26 families.

27 The member advisory committee worked very
28 formally with the provider committee in designing the

1 implementation of CalOPTIMAs mission, structure, and
2 goals, and many of those documents are available to the
3 Task Force in formally looking at the CalOPTIMA program
4 there in Orange. That meant we were even participating in
5 deciding the number of board members for CalOPTIMA and
6 where those board members would come from. So it was a
7 wonderful day when that board was together and it adopted
8 our admission which was to ensure that members values and
9 needs are integrated into the design, implementation,
10 operation, and evaluation of CalOPTIMA.

11 I still think in my experience, and I have
12 been a nurse since 1971, that this mission statement is
13 revolutionary in many ways. I think while we have some
14 intent to involve members to clearly make it part of the
15 mission of the organization and even the operation of
16 evaluation, it's not something that I see in most
17 organizations.

18 The board adopted our goals, which were to
19 communicate and advocate for members' needs, and the
20 structure of this committee answers directly to the board
21 of directors of CalOPTIMA. This committee is not placed
22 in a member services department or somewhere far away from
23 the power structure. It serves directly under the board
24 of directors and answers to the CEO, the CEO attends
25 almost every monthly meeting. This committee serves as
26 resource to the board and to the staff. Its goal is to
27 reflect community diversity and to communicate CalOPTIMAs
28 role in creating a healthier community.

1 When we organized this committee it was very
2 important to members of the CalOPTIMA member advisory
3 committee that some day this organization not only serve
4 Medi-Cal patients, but it also serve the indigent in
5 Orange County, and I know since I've left that's been more
6 of a focus of the organization.

7 As I say just to give you some examples and
8 evaluation if you look at the mission and goals you will
9 see the very values that are identified in this research
10 incorporated clearly into the mission and goals. Our
11 organization participated in the recruitment of the CEO
12 and setting the marketing guidelines in all of the member
13 orientation information, even though at times it meant
14 slowing down bureaucracy because materials were created to
15 go out to the beneficiaries and once our committee got at
16 it they required many, many, many changes. But we found
17 that even though all of our work slowed things down, in
18 the end most things were much, much improved. We were
19 even involved in helping to design the provider
20 contracting structure as well as looking at and
21 participating in continuous quality improvement actives.

22 My hope is, as the system is only up since
23 October of '95, that as we move forward we will be able to
24 see that we were able to decrease the costs of care from
25 Medi-Cal beneficiaries in Orange County; that we're able
26 to improve quality of care to provide more choices and to
27 improve access.

28 Certainly I know, having lived in Orange

1 since 1979, that there are definitely more choices of
2 those 300,000 beneficiaries. Before CalOPTIMA only 50
3 percent at any given time of those people had access to
4 needed medical care. I remember sitting in rooms with ten
5 or more pregnant women who were dialing for doctors,
6 looking for physicians who would serve this population.
7 So even though we had the card people didn't have access.

8 And then finally before I move on to this
9 next consumer feedback loop, I did want to say that one of
10 the things that the chairman asked me to do is to think
11 about, oh, incentives, regulation, and the kinds of things
12 that this Task Force is looking at. And I did want to say
13 that one of the things that made this work is that the
14 James Irvine Foundation provided a grant to California
15 Health Physicians so I could volunteer my time in creating
16 and working on this member advisory committee, that I
17 could hire staff. And I think as we are looking at the
18 other Medi-Cal systems throughout the state we really have
19 to consider that this was a very labor intensive process;
20 the amount of reorganizing that went here, and I think
21 looking for putting some dollars into this whether private
22 or public is very important.

23 Estella Martinez is here and before I move
24 onto this next section I thought if you have some
25 questions for Estella about this particular program I
26 would stop here before I move on to the consumer feedback
27 group.

28 Alain, would you like me to do that or do

1 you want to barrel through and put the lights back on and
2 have questions for everyone.

3 MR. ENTHOVEN: I'm worried about the time
4 element. I wish we had more time.

5 MS. SEVERONI: Okay. So barrel through.

6 So I will come on down. Let me go back here
7 and say -- all right.

8 Now we are talking about the consumer
9 feedback loop. This is a model for improving health care
10 quality that involves patients, providers, purchasers, and
11 health plans in a consumer driven process of research,
12 solutions, change, and evaluation. This is what it looks
13 like. You will see this figure as it goes through again
14 and again. I think you'll note with me that the missing
15 link to this point has always been putting the employee
16 and the patient, I think, at the same table with the other
17 decision makers as we're looking at system changes.

18 And we'll move very quickly to say in each
19 of these projects, that I'll just barely highlight, each
20 project requires that a team be organized, that a mission
21 vision guiding principals and goals be agreed upon and
22 resources be committed.

23 There are four steps in each one of these
24 projects. The first one involves research with both
25 enrollees as well as providers. The second step is once
26 we get that information gathered, we design solutions with
27 the full team. We then implement changes, and the fourth
28 step is to measure and evaluate.

1 The very first project that was done, these
2 have only been begun as of the last couple of years, was
3 with the St. Joseph Health System was the employer, the
4 Orange Coast Managed Care Services, the Physicians or
5 Medical Group, the St. Joseph Health System, the employer,
6 sorry, the employees and Pacific Health Care Plan. This
7 was the very first project the CEO of the health system
8 came up and said our enrollees are unhappy in managed
9 care, can you take those set values and create an
10 evaluation tool. I said I would be happy to do that but
11 only if he agreed to bring the health plan and the
12 provider group to the table to correct or improve those
13 concerns that the enrollees had because the last thing we
14 need is another market research firm these days telling us
15 more about what's wrong. He agreed to do that; the team
16 came to the table.

17 There were three key areas that bothered the
18 enrollees: One, they don't really understand the use of
19 the E.R. and are very unhappy with that; secondly, they
20 don't think they get the information they need to choose a
21 primary care physician, they get lots of pictures they
22 don't really get the information that's helpful to them;
23 thirdly, very dissatisfied with the referral process.
24 This team decided they wanted to focus on their referral
25 process; they redesigned that process. You got
26 information about that in your packet if you want to look
27 at some of the specifics, and as part of that we created
28 just a very simple tool for all physicians to use in those

1 offices on patients that need to be referred, which is it
2 simply tells patients and doctors what are the next steps,
3 whose responsibility is what, helps them more easily
4 through the system.

5 Now what happened around that time -- and
6 I've got two gentlemen here today who will be happy to
7 answer your questions and expand a little bit on this
8 model, Bo Carter from the Integrated Health Care
9 Association, which is an association of managed care
10 organizations health systems, health plans and employers,
11 came down to visit me and was very interested in that
12 feedback loop and wanted to know whether or not we were
13 interested in replicating it. He came back, met with
14 several members of the board of directors, some of them
15 being people from Chevron, Health Net, and Hill
16 Physicians, and this set of people decided they wanted to
17 recreate this project.

18 Today we have with us the president or,
19 excuse me, the executive director of Hill Physicians
20 Medical Group; I think you'll want to ask him some
21 questions regarding their involvement.

22 The purpose was to identify and respond to
23 employee concerns about health care services, to involve
24 those enrollees along with representatives from all of the
25 organizations at a project planning table from the
26 beginning to identify those issues, and those issues
27 turned out, again no surprise, to be an access referrals
28 claims and billing; and to develop process improvements,

1 four of them, to be exact, and here they are.

2 This team is broken down into several teams
3 that are looking at, (a) redefining financial criteria for
4 pass through procedures in this organization. This has to
5 do with the authorization process, people are still having
6 difficulty and consumers do not separate the referral and
7 the authorization process. It is all one big nightmare
8 for most people as we make our way through these systems
9 and regardless of how hard the systems are trying they're
10 just still not here.

11 Second marker is to improve physician staff
12 patient communications with regard to this referrals and
13 authorizations. The third was to enhance communications
14 between the health plan and the employer to the enrollees
15 with regard to authorizations. And finally to entirely
16 remove the enrollee from claims and billing issues as soon
17 as they're identified.

18 This is one process in the improvement that
19 happened immediately. We're in third phase where you can
20 see some of these things are going to take months of work
21 but both the health plan, which is Health Net here, and
22 Health Physicians agreed immediately to -- when an
23 enrollee calls with a billing problem, to keep that
24 enrollee on the phone until one or both of those
25 intuitions can resolve that. So it will be very
26 interesting to see how what that will mean to a
27 satisfaction.

28 The industry is getting pretty excited here

1 because now we've got another one of these loops this time
2 with CalPERS, Health Net, and four provider groups. And I
3 just want to show you this is a state-wide affair because
4 again the four provider groups are once again Hill
5 Physicians Medical Group, and we have someone here, Steve
6 McDermott, Alta Bates (phonetic), Medpartners, and Scripps
7 (phonetic). So this is now a state-wide project.

8 The interest here, again as I move very
9 quickly, is to stay focused, stay focused on that referral
10 and authorization process and to look now for best
11 practices. This is the first time in a project of this
12 nature that four competing provider groups are coming to
13 the table partnering with a health plan and major
14 purchaser all to focus in on enrollee driven concerns.
15 The Medical Quality Commission has joined us in this
16 effort -- they are an accreditation and education
17 organization -- their interest is in helping to spread and
18 develop the best practices and help us move those across
19 all or as many medical groups as possible in the state.

20 Finally, and because we're again talking
21 about Medi-Cal managed care, I think I'm most proud of the
22 fact that we've got two health plans that have agreed to
23 come to the table in creating one of these projects, the
24 Alameda Alliance for Health and Blue Cross of California,
25 two competing plans this time agreeing to come to the
26 table with Medi-Cal beneficiaries in Alameda County. Five
27 physician representatives, two hospitals, and the
28 Department of Health Services all focused in again on

1 beginning with enrollee concerns starting from that point
2 and building as a team. I'll just show you about what
3 this team looks like when we put all these partners down.

4 Working as a team to evaluate this system,
5 the focus, of course, in enrollment right now is with aid
6 to families with dependent children. We'll be starting
7 actually at the end of this month with our enrollee and
8 physician focus group, and we're looking at addressing the
9 entire process. In other words, we're not focusing only
10 on referral and authorization, the beneficiaries will tell
11 us what they're most concerned about and then the teams
12 will work together to move forward.

13 Again, back to incentives. Let me say on
14 this Medi-Cal project this is entirely grant funded.
15 Those are the three organizations up there that are
16 providing the dollars to do it. Right now our budget is
17 working around \$350,000 over two years to do this work.

18 On the other projects there's a mixture of
19 pain. On the Chevron project, Dole (phonetic) Physicians,
20 and Health Net are sharing payment for that project. On
21 the CalPERS project CalPERS and Health Net are paying. So
22 I think we may -- if you think these are worth while
23 efforts you may want to again think a little about the
24 packets.

25 I'm going to put the lights up again. I'm
26 going to say that we're very early on in this work. As
27 you can tell there's been a tremendous response from the
28 industry just in this past year. I mean we've literally

1 just finished the first model and already have three
2 replications with some requests for more.

3 Now that the lights are on I would like to
4 introduce my colleagues just again to you. Estella
5 Martinez from CalOPTIMA Program in Orange. Steve
6 McDermott, the executive director of Hill Physicians; and
7 Bo Carter from the Integrated Health Care Association,
8 executive director. Just a quick reminder that is the
9 association that brought us up to its board of directors
10 and said what do you think about this and has essentially
11 helped us get the other projects going, open it up.

12 I hope I did that quickly.

13 MR. ENTHOVEN: That's terrific, that was
14 extremely interesting. I can see many excellent elements
15 in there including it's continuous quality improvement and
16 how that ties in sort of model which is very valuable.
17 And also it gets people involved in resolving the system
18 design issues at the local level, which is the best place
19 for it to happen. So I think this is wonderful.

20 I'm being brutally oppressed by the clock.
21 So before we go into questions with your panel, I would
22 like to call on Jeanne Finberg and then we'll have a
23 question and answer general discussion.

24 MS. FINBERG: Hi, I'm Jeanne Finberg, I work
25 for Consumers Union, which is the nonprofit publisher for
26 Consumer Reports magazine. I'm passing around some things
27 which there's plenty of copies that will be available for
28 the public too which I'll distribute when I'm done.

1 Consumers Union has been testing products
2 and informing consumers for its 60 year history, and since
3 the very beginning of the organization we have been
4 interested in transmitting information about health. Our
5 very first issue was on milk and on health hazards with
6 milk.

7 I work at the West Coast regional office,
8 which is based in San Francisco, and it's an advocacy
9 office so we perform the protect function to advocate
10 inform and protect consumers about issues and, of course,
11 the organization has been involved in health reform issues
12 for many, many years, 30 years, and the West Coast office
13 has focused on managed care issues in particular as the
14 market has switched so rapidly to managed care in
15 California.

16 In terms of consumer -- and I'm going to
17 talk about two things, but I'll be very brief, and the
18 reason I'm passing so much paper is for you to take home
19 so you can read it later. In terms of consumer
20 involvement, we consumers here in the West Coast office of
21 Consumers Union is involved in a project right now
22 involving the Medi-Cal managed care program in California,
23 the two plan model which is in existence in the twelve
24 counties. We are working with the consumer
25 representatives which -- who are supposed to sit on
26 advisory boards or committees of both local initiatives,
27 the county run system, and the mainstream plan, and also
28 consumer advocates that are working with Medi-Cal

1 beneficiaries organizing, educating, and training those
2 people.

3 Just to give you one idea of some of the
4 challenges of a project like this with regard to the
5 consumer representatives, we've had a lot of trouble
6 getting a complete list of who the representatives are and
7 some of it is that not all of the plans have appointed or
8 found their consumer representatives yet and so we thought
9 there was a reluctance on the part of some of the local
10 initiatives or the mainstream plans to tell us that they
11 didn't have any. But now I've gotten an official formal
12 response from two local initiatives in Riverside and San
13 Bernardino telling us that they have consumers reps, but
14 they won't tell us the name because it's a violation
15 of confidentiality. I got the same response from Blue
16 Cross, one of the mainstream plans. I think we can work
17 through it; I think they're wrong that the representatives
18 should be known to the other Medi-Cal beneficiaries, but
19 it just gives you a flavor of how difficult it is to work
20 to organize consumer representatives.

21 I want to focus mainly on consumer
22 information and some of the struggles that we have at
23 Consumer's Union and Consumer Report in obtaining the
24 information we think we need to adequately judge and
25 communicate with health plans, health providers, and to
26 communicate that information to consumers.

27 I passed around the two Consumer Reports'
28 articles that we published last year on HMOs. The first

1 one "How Good Is Your Health Plan." You guys have
2 reprints so you don't have the nice color, but if you buy
3 the magazine you can have the color, and then the -- or go
4 to the library, which most people do when they buy a car,
5 apparently. And then the second -- the first was August,
6 the second was in October, and the second issue deals more
7 with some of the financial issues about trends and what's
8 happening with managed care.

9 We get requests everyday for more
10 information about health plans and about making choices,
11 and we would very much like to issue annual report cards
12 or more detailed information about health plans and we're
13 struggling to try to fulfill that need but we can't do it.
14 We don't have the information that we need that can
15 reliably be used to measure the quality of care and to
16 compare the plans, and we're finding that it's very, very
17 difficult to obtain.

18 In our surveys, and that's reported in the
19 August issue, we used our annual survey, which we survey
20 our members, which is a good tool but obviously our
21 subscribers of Consumer Reports are not reflective of the
22 general population, it tends to be a more wealthier, more
23 educated and not very diverse population.

24 And secondly, we use the HEDIS measures,
25 which we got from the plans voluntarily. Some plans
26 actually refused to give us the data, and they were, of
27 course, under no obligation to do that. But most of them
28 did, but just the larger plans participated in the

1 national basis and we found -- I just wanted to mention
2 although HEDIS is becoming rapidly recognized as the major
3 source of information and important developing instrument
4 for measuring quality, there are some pretty serious
5 limitations on the HEDIS data.

6 First of all, as a process measure that is
7 available now it doesn't measure quality. If we look at
8 the plans and see which plan gives more mammography
9 screens to its members, it isn't necessarily the basis of
10 choosing a health plan. If I were choosing a health plan
11 I would ask for the mammography screen as opposed to
12 waiting to get a postcard for it. So I wouldn't think of
13 that as a reliable indicator for choosing a health plan.
14 It would be different if they were denying the screen and
15 that goes to utilization, which I'll mention in a minute.

16 Also the plans are inconsistent in the way
17 that they measure the data and there are inadequate data
18 collection systems making it insufficient information to
19 judge how well the plan serves their members. It's also
20 very expensive. First it was \$100,000 cost to
21 participate, so the very small plans don't do that, but
22 beyond the cost to participate is really the cost of
23 collection and that's where the real financial burdens are
24 for the plans and why we need more uniformity. I think
25 it's in hundreds of millions of dollars U.S. health care
26 total; it costs them 300 million to put those computer
27 systems in place.

28 HEDIS is now collecting utilization data so

1 we know how many procedures per one thousand enrollees are
2 being done on gallbladder surgery or prostate removal,
3 coronary bypass, but these are not risk adjusted numbers.
4 And so it's information but it is very difficult to use as
5 a measure between the plans.

6 Additionally, we don't have the benchmarks
7 for what's good. Even if it were risk adjusted, it's very
8 difficult at this point to determine because of the
9 state-of-the-art how many per a thousand gallbladder
10 removals is appropriate for this population. So we're
11 very behind on the state-of-the-art. The enrollee survey
12 can measure some of the issues that are important to
13 consumers that we call the service issues, the waiting
14 times, response to grievances. We can also ask consumers
15 if they get the care that they need, but we find there is
16 a gap between what consumers want or think that they need
17 and what they actually might need or might want to know if
18 it were available to them. Now we're finding most of the
19 surveys are showing that consumers are choosing plans
20 based on cost, primarily based on cost, but it is the only
21 reliable indicator that we're giving them. So I don't
22 think we can conclude that that's the issue of primary
23 interest to consumers.

24 The plans are very reluctant to reveal
25 utilization data. Our reporters have found it virtually
26 impossible to get that level of information that they
27 need. The industry is very cautious about revealing
28 information that they consider proprietary or a trade

1 secret. It's not a just general private commercial issue.
2 The health care HMO industry seems to vary from some of
3 the other industries that we have surveyed and evaluated.
4 And a notable example for that would be the long-term care
5 industry which Consumer Reports hasn't been particularly
6 kind to but we found it easier to get the type of
7 information that we could use to measure quality.
8 We think information regarding utilization service and
9 specific disease management are the three areas that would
10 be essential for us to be able to report on plans the way
11 we believe it's necessary.

12 I mentioned the utilization problems.
13 Specific disease management, there has been some progress
14 in this area, some plans have some particular programs
15 where they're showing good results. They are reluctant to
16 divulge a lot of this information because of selection
17 issues. If a plan shows that they're the best plan for
18 treating HIV, then they will have the sickest most costly
19 patients or similarly for diabetes, etc. So we need to
20 figure out a way to avoid that problem and to get that
21 valuable information for consumers that have a particular
22 condition.

23 With service issues enrollee surveys, we
24 have not perfected the art there. We found that our data
25 doesn't really match with NCQA's data on enrollee survey
26 and that other report card data is extremely variable on
27 some of those consumer satisfaction issues. And so that
28 concerns us as an indication that we haven't appropriately

1 developed the measure. There are some major survey
2 enrollee survey efforts ongoing but in addition to NCQA
3 the HICFA, the Health Care Financing Administration, is
4 going to do a big enrollee survey with the federal law and
5 we believe that there should be more consumer involvement
6 in development of those enrollee surveys so they can be a
7 better measure of what we're trying to judge.

8 A missing piece in consumer information,
9 which was mentioned a couple of times earlier today, is
10 development of information at the medical group and
11 additionally at the physician or primary care provider
12 level. The medical groups mostly, except notably for
13 Kaiser plans, contract with medical groups to provide
14 their care. And in California there are almost three
15 dozen medical groups but there's only about a half dozen
16 or four or five medical groups that all have the big plans
17 views. And if we are -- if many, many important decisions
18 are delegated to the medical group, and if we are
19 measuring quality and we are comparing the health plans
20 that are using the same medical groups, what really are we
21 communicating to consumers? I think we need to breakdown
22 these issues and factors to identify that.

23 In the third piece of paper that I passed,
24 that I'm sorry you all have to take home with you, is a
25 short paper that I put together at the request of a
26 foundation about some of the issues around primary care.
27 And some of the paper is not relevant to this discussion
28 but it does identify some of these issues about

1 information that's needed at the medical group level.

2 At the physician level there is also little
3 information. This isn't necessarily a managed care issue,
4 choosing a doctor and the difficulty of communicating
5 information about physician choice is -- has always been
6 around in the fee for service system and the managed care
7 system but there are certain aspects of the gatekeeper
8 function and the lock-in feature of the managed care that
9 make it even more crucial decision.

10 We think -- of course there's a lot of
11 information about physicians that would be helpful to
12 consumers to communicate. One of them might be
13 utilization, and one of the issues that consumers are most
14 concerned about is the pressure on physicians to restrict
15 care. And it seems likely that some physicians are less
16 pressured than others, that some are better advocates for
17 the patients than others within the plan in terms of how
18 to manage the system. That's the kind of information that
19 would be very helpful for us to be able to measure and to
20 give to consumers.

21 We can't test HMOs the way we test cars,
22 although we have been requested to do that, but we can't
23 take testers with various medical conditions and send them
24 off to plans and see what happens to them. So as a
25 result, we need more standardization of information and
26 more cooperation with the plans or required disclosure so
27 that we can do our job disseminating information.

28 Thank you.

1 Is that quick enough?

2 MR. ENTHOVEN: That's excellent, thank you.

3 Thank you very much.

4 I think that you've made some tremendously
5 important points and I'm sure many of us share your
6 aspiration of where we need to go. I think at least among
7 people I associate with that we share your frustration
8 over the lack of information and can see the long way to
9 go in the future. I think the lack of quality measurement
10 is among other things a legacy from the previous
11 non-accountable system where it's only lately that we've
12 had entities that we can hold responsible that we can say
13 now measure your quality of importance to us as well as
14 the difficulty. Ellen is on the board of the foundation
15 for accountability and they are making progress.

16 Some of the very important concerns that you
17 raised, Jeanne, the Pacific Business Group on health is
18 addressing such as reaching through to the medical groups,
19 standardization, auditing. We have a California
20 Cooperative HEDIS Initiative, CCHI, and we are asking
21 somebody from PBJ, who is very much involved in these
22 issues, to speak at our July 26th meeting so we'll have a
23 presentation about what they are trying to do. And
24 they're not close to there yet but they are addressing it
25 so I hope you'll participate in that discussion.

26 What I would like to do is open it to
27 questions and discussions from the Task Force.

28 Let me say with respect to -- without

1 objection I propose that we continue this meeting until
2 1:00 or 1:15 in order to get our work done without cutting
3 this discussion too short, and we can grab a quick bite on
4 our way to the hearing.

5 Could we start with some of the presenters
6 who have come. Do you have other comments you would like
7 to add? And then we'll have questions and discussion of
8 the Task Force.

9 MS. MARTINEZ: Thank you very much for the
10 opportunity.

11 I just wanted to briefly comment a little
12 bit about the member involvement and CalOPTIMA. It was
13 because of the input of the consumers that really
14 CalOPTIMA is in existence today, and I would like to give
15 credit to those people who work so hard on it, but more
16 importantly I would like to talk with some of the things
17 that the committee accomplished. And I must say as a
18 staff person it has not been easy for me coming from the
19 bureaucratic side to deal with the consumer side, but I
20 think importantly as Ellen mentioned the committee was
21 instrumental in the development of the health services
22 requests for proposal. We initially contracted with 34
23 health plans in Orange County. Unfortunately now we're
24 down to 19, but that process wouldn't have happened as
25 smoothly as it did without our member involvement. They
26 helped us develop the contract and put in the consumer
27 issues that they were so concerned about.

28 There are also currently, as we talk about

1 quality, developing benchmark information that they want,
2 that the member advisory committee wants to obtain across
3 all of our networks so that they can obtain the various
4 quality indicators they feel that they need to have to
5 make decisions about redesigning or modifying our program.

6 Also they have and are working on the design
7 and analysis of our AFDC member satisfaction survey. We
8 have had bumps in the road, some very large, some smaller,
9 with our disabled population. We are mandatorily
10 enrolling the SSI population to the medical managed care
11 program, and they are and our member advisory committee is
12 working with us on our quality management work groups to
13 identify access and barriers to care to help us overcome
14 those. And they have encouraged us to develop such things
15 as wheelchair seating clinics, authorization guidelines
16 such as six-month authorization for incontinent supply
17 guidelines that they feel are really key issues for
18 members with disabilities. They're also interested in
19 standardizing guidelines across the networks so our
20 Medi-Cal beneficiaries when they change from plan to plan
21 the system is same; they're also sitting members on our
22 grievance committee. Approximately 30 percent or three
23 members of our grievance committee are members of the
24 community of our member advisory committee and they helped
25 us develop and modify our grievance and appeals procedure
26 because they didn't like the way we put it together, so
27 they decided to change it.

28 And again quickly to emphasize the important

1 role they play, they report directly to our board of
2 directors, they are not a group that sometimes gets
3 together and just sort of pats each other on the back for
4 coming to meetings and eating cookies. They're a working
5 committee and we staff them, we think appropriately.

6 So those are the few comments I wanted to
7 make.

8 MR. ENTHOVEN: Thank you.

9 MR. MCDERMOTT: I'm Steve McDermott, Hill
10 Physicians Medical Group.

11 When Ellen and Bo proposed the idea of the
12 consumer feedback loop, I had no idea when they proposed
13 it what this thing was going -- what form and shape and
14 how much energy it was going to take. What I will tell
15 you though is after being in the managed care industry for
16 15 years, it was the first time, amazingly to tell you
17 what an infancy this business really is, it is the first
18 time I was in a room with the health plan and employer at
19 the same time talking about, you know, online real time
20 issues of service and quality. And Ellen will tell you I
21 wasn't exactly thrilled when they said they were also
22 going to add actual consumers particularly when -- and
23 Ellen knows -- how are these people going to be selected?
24 And the answer was, well, it's the squeaky wheel and sure
25 enough a mother of -- who is in Hill with a child who had
26 special problems who had been very, very unhappy with Hill
27 Physicians was the consumer who was put on the task force.

28 And now having said that, it was a terrific

1 experience for our organization having both the health
2 plan -- the employer, and I think the more important thing
3 the employer and the consumers themselves on the task
4 force. And we were doing a lot of work at the time anyway
5 but this thing really put octane in the process and made
6 it much more important to us then it might have otherwise
7 been.

8 Ellen now is saying, you know, because she
9 comes out of the nonprofit sort of community based
10 approach, that it should be voluntary. I'm not sure I
11 agree with that. The benefits of having a lot more
12 exposure to what we do and the accountability that comes
13 from exposure is very important and I don't want to
14 understate it.

15 The other side of the coin the benefits was
16 it was very clear in the conversations that the employers
17 had very little -- the buyers, if you will, who represent
18 their employees had very little understanding of how the
19 system actually works on a day-to-day basis, and their
20 education and interaction had been largely with the health
21 plans. And as was just said by Consumer Reports is that
22 the product is really delivered by the underlying medical
23 groups and that's largely invisible and it's not 30 it's
24 closer to 300 and it's grossly unregulated and it's at
25 best patchwork quilt. And it's very agonizing and
26 difficult process to create really organizations, entirely
27 new organizations that are trying to attack underlying
28 fundamental problems in the non-system that include

1 dealing with very intense powerful special interest
2 groups, namely the specialist.

3 We all know -- do I not pull my punches?

4 We all know that --

5 MR. ENTHOVEN: Please continue.

6 MR. MCDERMOTT: We all know Kaiser -- and I
7 did my original management training in Kaiser in Northern
8 California in 1969 and '70 -- Kaiser is a good system,
9 excellent system, actually, but it is a one-to-one ratio
10 of primaries to specialists. And I will tell you I know
11 doctors in Kaiser who used to be the in private fee for
12 service sector who say I do better medicine in Kaiser.
13 It's more boring; if today's Tuesday, it's gallbladder
14 day, you know, but they have the same team doing the same
15 work with them day in and day out.

16 I can tell you that there are private
17 surgeons who on any given day will do surgery in three or
18 four locations. They may not know the staff they're
19 walking in on, they may in fact while they're doing the
20 surgery be on all call at two or three E.R.s. This is a
21 historic totally unregulated, unmanaged industry outside
22 of Kaiser. And when I started Hill Physicians in 1985 I
23 literally thought it was going to be -- because I had
24 designed and help build the original 911 and emergency
25 medical system in the '70s -- I thought it would take us
26 20 years in 1985 to create an organized delivery system,
27 if we could even do it in 20 years of the non-Kaiser sort
28 of rest of the world. And we're 12, 13 years into that

1 process and I think we're kind of tracking on time, which
2 is sort of good news bad news.

3 But on our side of the coin, which is the
4 non-Kaiser health care delivery system and non-county
5 delivery system, we're fundamentally dealing with one
6 primary care physician for about five or six specialists
7 and that doesn't work.

8 You know sometimes I think it would be
9 easier to toll the whole process until all these guys
10 retire and U.C. stops putting out so many specialists, in
11 about four or five years they'll stop doing that, but for
12 those of you like myself who are impatient and very, very
13 unhappy with anybody who has been in health care as long
14 as I have knows all the things that has been wrong with it
15 and they're impatient to get to those issues, then I'm not
16 going to wait for these people to retire. And so when you
17 accept that then you take on a very difficult task and
18 that's the task we're in.

19 Now having said all of that, as a
20 consequence what I will tell you is we do not have -- the
21 individual PCP capitation is a technique which is used in
22 about 80 percent of the industry, it's pretty much of a
23 bad idea. If you're in business it's a bad idea from a
24 business point of view. Primary care is most care for
25 people most of the time. It's really -- you want really
26 easy access to primary care, and if you capitate your
27 primary care physician it's sort of like the wrong thing
28 to do.

1 Hill Physicians has never capitated to
2 primary care physicians. We've never done a withhold on
3 primary care physicians. Our primary care physicians are
4 incentivized to see people and see them as much as they
5 can.

6 One of the techniques in the industry,
7 however, which is, you know, an industry that says
8 managing doctors is an impossible task so let's just
9 capitate them and be done with it; so they capitate
10 primary care physicians and I think a lot of access
11 problems, not all access problems, but a fair amount of
12 access problems comes out or borne out of that sort of
13 technique.

14 Now having said that, access to specialist
15 is another issue, and I would challenge the thinking
16 process -- and Ellen and I go back and forth on this all
17 the time when she shows her last slide which is, you know,
18 the results are better increased access and increased
19 speed in the referral process. I don't know that that's
20 such a good idea. Too many specialists can be not good
21 for your health.

22 And so we have, in spite of that, primary
23 physicians and Hill Physicians have been able to do direct
24 referrals to specialists without getting anybody's
25 approval. They can do that. And the specialists have a
26 limited authorizations to go treat without getting
27 authorization. And we also have direct access by
28 consumers to OB/GYN, and for the past two years to mental

1 health. I think mental health is grossly under funded in
2 health care and Hill Physicians typically spends two to
3 three times what the average medical group spends on
4 mental health because I think it's so unrecognized.

5 But as far as referrals, once the patient
6 has been seen by the cardiologist or the orthopod that at
7 that moment in time if it's an elective process I want to
8 slow everything down. I don't want to be high noon and
9 mono, mono, okay, so that that patient who walks into that
10 doctor's office, into that orthopedists office under the
11 old regime, the fee for service regime, that maybe the
12 16th patient that the doctor is going to spend 10, 15
13 minutes with that patient and make a \$25,000 decision.
14 That's not smart; that's not good medicine. But it is the
15 old style of medicine one-on-one. The old sort of
16 sanctity of the doctor/patient relationship, which is a
17 bizarre power curve in favor of the doctor. I want at
18 that point in time the doctor to gather information and
19 then to share that information with other physicians in
20 his own field or her own field and think about it and
21 think about not -- and also I want to remove as much as
22 possible the economic equation.

23 Now I'll stop, I'm sorry.

24 MR. LEE: I love this discussion. And we
25 are going to have other meetings of the Task Force and we
26 need to go into the role of medical groups, consumer
27 education issues, and consumer power. And I would love
28 for you to come back and have a discussion about the

1 interface where medical groups play, etc., but I'm a
2 little concerned about having questions for the other
3 folks that spoke and -- but depending on all the issues we
4 need to come back around and talk about it, but this
5 wasn't the forum for that.

6 MR. MCDERMOTT: Thanks Peter, I'm sorry, I
7 don't feel strongly about this at all, and those know me
8 also.

9 And that's the last thing I actually do want
10 to say and that is we make a mistake sometimes in thinking
11 that the shortest period on the authorization process is
12 better and we deliberately at that moment in time if it's
13 elective try and slow the process down and get a lot more
14 information and that's really what we mean by medical
15 review, what some people call utilization review.

16 Thank you very much.

17 MR. ENTHOVEN: Bo, do you want to --

18 MR. CARTER: Steve has conceded me the
19 balance of his time, which is about one hour. I'll be
20 very, very quick.

21 I represent Integrated Health Care
22 Associations which is a collection of HMOs, medical group
23 large systems, hospitals, plus an academic business
24 purchaser and consumer, and we're basically looking for
25 both policies and projects that will increase the
26 responsiveness of managed care, its accountability, its
27 performance.

28 Ellen and I talked first about the consumer

1 feedback ones because we were clearly looking for some
2 projects that had an active consumer role, not looking at
3 patient satisfaction data after the fact and figuring out
4 how you might design a new health care product or new
5 procedure, but putting consumers at the table. So we were
6 delighted to have the benefit of her first model and to be
7 able to create the first one we did, which was Hill
8 Physicians, Chevron, and Health Net, and then the second
9 one with Alameda Alliance and Blue Cross. And we're
10 looking for at least a third one in the Medicare risk
11 arena somewhere in the South.

12 Ellen has described the benefits of them. I
13 think four IHA as a group our larger interest is to be
14 able, we hope, to create some replicable models and tools.
15 They may not look exactly the same as other health plans
16 or other medical groups or other employers take them on,
17 but if they retain the essential feature of something that
18 is enrollee driven and sets the project from the point of
19 view of the consumer trying to navigate the system, then I
20 think they're going to produce more responsive and lasting
21 result.

22 MR. ENTHOVEN: Thank you.

23 Ellen, do you want to come back. The Task
24 Force members have questions.

25 Yes, Terry.

26 MR. HARTSHORN: I was wondering for
27 CalOPTIMA has it been around long enough where you can see
28 you're starting to meet some of the original goals which

1 Ellen mentioned lower cost, better access, higher quality.

2 Have you been able to get any output data?

3 MS. MARTINEZ: We have gotten some limited
4 data. Unfortunately, we all struggle with encounter data.

5 What we have seen is a significant increase
6 in CHDP exams for our children; that is something we have
7 been able to measure over time. So that is one indicator.

8 We're also noticing a more appropriate drug
9 utilization process for some of our difficult to manage
10 patients, our drug seeking patients. So there have been
11 some benefits that we can see right off the bat. But
12 we're now looking at some of the things that you were
13 talking about earlier such as disease state management,
14 programs for asthma, diabetes, etc., for our patients.

15 MR. ENTHOVEN: Steve.

16 MR. ZATKIN: I would be interested in
17 getting the thoughts of Jeanne and Ellen about the kind of
18 information that is most useful to consumers in making
19 decisions around health care organizations to the extent
20 to which that is available and how that corresponds to the
21 kind of information that's being developed by purchasers
22 and others.

23 MS. FINBERG: I think that the -- well, one
24 of the problems that I see or that we see at Consumer
25 Reports and Consumers Union with the efforts that are
26 going on is that they were set up by the industry and by
27 the purchaser's employers, and although there's a little
28 bit more effort now to have a consumer voice in that

1 system, it's a very weak voice. So one thing that would
2 strengthen those efforts, in our mind, is more consumer
3 participation. We prefer an independent, totally
4 independent evaluator from the industry. So from our view
5 the government or some other nonprofit entity would be a
6 preferable sight because we feel it's more reliable
7 information.

8 In terms of what kind of information will be
9 most useful, I'm trying to look at kind of what's missing
10 and there's a whole -- most of it's missing in terms of
11 quality measures, and there has been some work in
12 development of outcome measures that's obviously a various
13 complex task and will take a long time to develop, but we
14 need to do it faster and we need to do it better.

15 One thing that is available now is a lot of
16 the information that the plans themselves are collecting
17 and reviewing and using in their utilization review but
18 they're not telling. And that's the area where I think we
19 could change something immediately that it does exist and
20 if we required some type of uniformity and some type of
21 reporting that consumers would benefit I think probably
22 longer term the industry would benefit too from the
23 uniform nature of it.

24 MS. SEVERONI: I would just go on to say
25 that at this point the way we are reporting information to
26 consumers just doesn't seem to resonate very well or
27 clearly with them. I mean report cards -- I've yet to
28 have someone call my office, and I get many calls for many

1 things, but I have yet to have a consumer call and ask me
2 for that kind of information.

3 I really am -- would like to see us to try
4 to talk with some of the members of the fact team because
5 over the past three or four months they have spent a
6 tremendous amount of money and time doing some very
7 specific research with consumers and, you know, some of
8 the information that consumers want really resonates
9 around which are the organizations which treat me with
10 dignity and respect and, you know, will I be treated
11 fairly and openly. This is the kind of information that
12 people want.

13 One of the things that I see is that -- and
14 I think I told Allan (phonetic) about this at our first
15 Task Force meeting -- I get concerned sometimes thinking
16 that if you are all bad guys in the industry what you
17 would do is sit back and make all the offices clean and
18 spotless and put smiles on everybody sitting and waiting
19 and treat us in a wonderful way. Because there is an
20 assumption of quality by many, many consumers, and it's
21 because we lack any reliable tools. I mean why would I
22 even as a nurse go up against a physician who has medical
23 quality information or, you know, I don't have any tools
24 that help me do that. And I think we are still years from
25 having meaningful quality information; that's why I'm
26 spending a lot of my time volunteering for an organization
27 that's focusing on organizing that information so it can
28 be put in the hands of people, which I think is -- of

1 consumers which I think is our real challenge.

2 MR. ENTHOVEN: Dr. Alpert.

3 DR. ALPERT: Do you have a sense that
4 consumers are concerned with the amount of time they are
5 seen by physicians, being rushed as opposed to having
6 unrushed consultation? Do you hear that a lot?

7 MS. SEVERONI: Some consumers. Certainly in
8 any set of focus groups seem very, very tied in to the
9 stories that are in the media. And so it's hard for us
10 sometimes to distinguish are these events that are
11 actually happening to them or are they tying into the
12 stories. And our last few sets of focus groups have been
13 very closely related to a spat of stories that have
14 appeared in the media and so it's hard to distinguish
15 that.

16 But, yes, people do mention that they
17 believe that -- a lot of the information -- I just want to
18 say this that patients get about the health care system
19 comes from their physicians. And I would say to you that
20 I think if you wanted a very broad-brush statement from me
21 that I think many, many physicians are unhappy here in
22 California in most of these systems because of the
23 relationship between the patient and doctor is still very
24 sacred. Most consumers take that away. So I think if a
25 doctor is feeling rushed and is saying that this is why
26 she is rushed, that's taken away. If a doctor thinks that
27 there's going to be trouble with a referral, or even that
28 you don't need a referral, but they know -- sometimes

1 we've had physicians tell us in the physician groups it's
2 simply easier to put the blame on to the health plan, to
3 put them blame on to those restrictions rather than risk
4 the relationship that exists between the patient and
5 physician.

6 It's very hard to look at one group without
7 looking at both.

8 DR. ALPERT: That is what I was wondering.
9 I'm interested in the fact that, Mr. McDermott, that you
10 are part of this loop and experiment which I'm impressed
11 with and I would like to ask Mr. McDermott. You've
12 described the relationship that Ellen just talked about as
13 sacred as being a "bizarre power curve." You also said --

14 MR. MCDERMOTT: I did say that?

15 DR. ALPERT: -- you incentivize your primary
16 care physicians to see patients. How do you do that in
17 light of the issue of perceived lack of time and so forth?
18 How are primary care providers incentivized to see that?

19 MR. MCDERMOTT: Actually, two things. One
20 is the feedback we get is that they may be not thrilled
21 about the amount of time, but they're more unhappy about
22 the communication. The number one consistently year after
23 year the number one feedback we get back from our surveys
24 is that they are dissatisfied with the type and level of
25 communication. The doctor is --

26 MS. BOWNE: The doctors or consumers?

27 MR. MCDERMOTT: Of doctors.

28 MS. BOWNE: The doctors are --

1 **MR. MCDERMOTT:** The patients are
2 dissatisfied with the physician and, you know, the
3 research shows that -- and it maybe tied to the time,
4 okay, it is my belief that it is. Too many of our primary
5 care physicians, because we compensate them on a fee for
6 service basis, are seeing patients that they may not need
7 to be seeing, or frequently have a explicit or implicit
8 mental health issue and they should be seen by somebody
9 else. But they're seeing them nevertheless because that's
10 how they've been trained and that's the compensation.

11 We have been working on kind of a modified
12 fee for service in which we're doing sort of trying to
13 follow the business group on health and some other folks
14 in which we want to have, as part of the compensation,
15 tied to some of the issues you're dealing with right now.
16 Performance issues, that's number one, because that is --
17 there's none of that in any of the historic fee for
18 service system. And the second is we would also like the
19 physician to be thinking more about his entire population
20 of patients that they're caring for rather than simply the
21 one-on-one.

22 And we would also, lastly, like to -- and
23 when I see my primary care physician I would prefer to
24 talk to him on the phone about something and not bother
25 him about it, but he doesn't get paid under fee for
26 service for being on the phone, so that process -- and
27 we're looking at that to tie it in.

28 **DR. ALPERT:** Continuing with that, you

1 talked about having slow down phenomena. I assumed you
2 meant other consultations or you just mean
3 pre-authorization process?

4 MR. MCDERMOTT: Both.

5 DR. ALPERT: Usually it's not the
6 pre-authorization process but a singular type of
7 physicians.

8 MR. MCDERMOTT: I would like to slow it all
9 down.

10 What we've done over the years is increase
11 what we pay physicians for what we call cognitive codes,
12 that means we're paying our physicians more than the fee
13 schedule calls for to spend time with the patient. We
14 call it the basic history and physical, and spend a lot
15 more time getting to know the patient and talking to them
16 and compress what they get paid for actual procedures and
17 actual tests to achieve that balance and slow that down.

18 Second thing is to slow down the
19 decision-making process on an elective process to get
20 second, third, fourth -- to get a group of cardiologist to
21 look at the information rather than a harried cardiologist
22 on the fly seeing his 18th patient of the day.

23 MR. ENTHOVEN: I think we need to move
24 forward. We've got Clark Kerr, Peter Lee, Ron Williams,
25 and Hellen Rodrigues-Trias and then we'll stop it there.

26 Let's see, Helen.

27 DR. RODRIGUES-TRIAS: Thank you.

28 I think many of us have been involved over

1 the years in efforts to have this kind of consumer
2 participation from the beginning, but that it is extremely
3 difficult to institutionalize it and I wondered how you
4 see the perspectives of that becoming if this is the way
5 to do business -- being that you're needing all of these
6 external outside-of-the-system supports to have any kind
7 of input.

8 MS. SEVERONI: This is -- that's an
9 excellent question. I certainly haven't figured it out,
10 Helen. In the past few days, in fact, I've been meeting
11 and talking with people about it because the process is
12 expensive and there's a part of me that wants to turn now
13 to Steve and ask him if --

14 MR. MCDERMOTT: That's a great question and
15 if we had figured it out you wouldn't be sitting here.

16 DR. RODRIGUES-TRIAS: But what approaches
17 are you having? Obviously what are your thoughts about
18 where should we go?

19 MR. MCDERMOTT: I think we are sort of at
20 the bottom of the rude and crude process, and I think that
21 the consumer has been really the purchasers, the employer
22 groups, and their interest was in getting the cost down.
23 So guess what, surprise, surprise, that's what everybody
24 focused on. Well, we probably hit that bottom and we're
25 probably actually seeing an increase in cost, increase in
26 premium.

27 Well, the executives in the corporations are
28 saying, well, now, if you can't show me lower costs then

1 you better show me something. And so now the pressure is
2 on customer value and so forth. But also we've got to
3 blow past having the employer being the only consumer at
4 the table.

5 MS. SEVERONI: I can tell you, just to pick
6 up on that, that recently Health Net is the health plan,
7 they were in contracting with Pacific Business Group on
8 Health, and PBGH literally said this looks good but go
9 back and give us a consumer feedback loop and we'll sign
10 on the dotted line. That is the first now I'm hearing
11 that it's not mandatory. It is certainly coming from the
12 purchaser and I guess I was hoping the Task Force would
13 begin to help answer some of that question if you believe
14 there is value in these models.

15 Your darn right that they need to be
16 incentivized because there isn't enough goodwill to allow
17 that -- Patricia Moore who is the name of the enrollee who
18 sat down with Steve and his team and the other teams over
19 a period of several months, there is not enough goodwill
20 in the world to help an organization through that because
21 that was very painful and I admire all the bodies for
22 coming out in whole and being able to move forward. But
23 it takes tremendous will. So that's where my concern
24 about mandating things comes in because you couldn't
25 mandate Steve and his organization to sit at that table
26 through that. You couldn't make anybody do that. There
27 has to be a way to incentivize this so people who are
28 interested can see the value and move forward and maybe

1 there's some disincentives you might want to use. I
2 haven't figured that out; I'm hoping we can do that.

3 MR. ENTHOVEN: Ron Williams.

4 MR. WILLIAMS: Two comments and one
5 question. One to comment around information that we see
6 in terms of what consumers judge on quality. Consumers
7 judge often by things like parking, waiting time to see
8 the physician, how long it takes from the referral to
9 physically see a specialist, and the whole issue around
10 the communication going to the doctor and what the doctor
11 is saying, and that's a whole set of things that the
12 consumers represent symptoms of quality because they can't
13 judge.

14 The second point is to echo Steve's comment
15 and put a point on the distinction how health plans pay
16 medical groups and IPA verses how medical groups and IPAs
17 choose to pay physicians. And we talk a lot about
18 capitation and there's an implicit supposition that every
19 individual physician is receiving some per member per
20 month fee for every member in their practice and that
21 often is not the way it actually works. And I just want
22 that point on that.

23 MS. BOWNE: That's rarely the case.

24 MR. WILLIAMS: Second question is really for
25 Jeanne. I think that there is still a large population
26 both here in California and in the U.S. that are covered
27 by traditional fee for service plans. You talked about
28 utilization, service, disease management as three critical

1 dimensions. I'm curious if your organization has done any
2 work to evaluate the implications for utilization services
3 and disease management in looking at the millions of
4 consumers who are covered under fee for services. I would
5 be interested in comments you have had and or haven't had
6 and why.

7 MS. FINBERG: We have compared indemnity
8 plans and in fact we have done more of that than we have
9 with HMOs who are fairly recent to the HMO comparison
10 mission. But in terms of utilization I don't think that
11 we have directly compared it in the same way for obvious
12 reasons. Although, we did in 1992 a large series which we
13 then put into a book on health care system and did
14 document some of the waste and overuse of the system
15 which, although there was a little bit of managed care
16 then it was primarily the fee for service system that we
17 were illustrating what some of the wasted expenses were.
18 So that's probably the closest that we came in our
19 critique of the health system.

20 MR. ENTHOVEN: Part of the answer to your
21 question is with the fee for service system on the issue
22 of disease management is there's no accountability
23 structure and one of the things with managed care is
24 there's somebody you can hold accountable for it. I
25 realize your feelings on unequal standard here.

26 MS. FINBERG: The other thing is too without
27 the lock-in feature of the managed care plan the consumer
28 can walk with her fee to a different doctor, go directly

1 to the specialist, get whatever procedure she wants, if
2 she's willing to pay for it. So that is an important
3 difference.

4 MR. WILLIAMS: It doesn't speak to
5 utilization service and disease management and I think the
6 old adage about the attorney who represents himself,
7 there's a statement about that and I think any of us
8 trying to -- there's a corollary statement to those who
9 try to treat themselves. I would encourage us to look at
10 are there similar corollaries in the service and disease
11 management and fee for service system that might be an
12 area.

13 MR. ENTHOVEN: Clark.

14 MR. KERR: I think access and satisfaction
15 and dignity and parking and everything else is important,
16 but I'm very concerned about outcomes and I think
17 ultimately that's what consumers are going to be most
18 concerned about and we know there's huge variations of
19 practice patterns in California and around the country.
20 We are also learning there are huge outcomes too and the
21 last six months Johns Hopkins did a good study in the
22 State of Maryland and found in treating G.I. surgeries,
23 gastrointestinal surgery, there were 247 percent
24 differences in mortality depending on the hospital you're
25 going to.

26 We've had some data, nursing data, reported
27 to us on one of our health commissions that RAND in the
28 last couple of weeks looking at treating MIs, heart

1 attacks in the State of California, and it was very
2 interesting to note after all the risk adjustments that
3 RAND could do -- admittedly not perfect but RAND is pretty
4 good at doing this kind of thing -- if you looked at the
5 hospitals in California that were doing 200 or more of
6 these a year there was still about a 250 percent
7 difference in mortality depending on which hospital you
8 went to. And if you look down, further down, you get
9 statistically less significant. But if you look at those
10 that did 50 and more heart attacks a year there's 1,000
11 percent difference in risk adjust mortality.

12 I think this is critical and I think parking
13 and dignity and all that is important but I think whether
14 you live or die and function is more important and so I'm
15 wondering how can the panelist give us any ideas how we
16 can grapple with what I think is going to be a level of
17 more importance than perhaps some of the other issues.

18 MS. SEVERONI: My gut reaction to that is
19 basically I do believe consumers can learn how to use that
20 information. It is important. I mean some of the focus
21 groups I've been involved with -- in fact it takes some
22 drilling down, Clark. It isn't up on the top. It takes
23 drilling down into the focus group to get people to think
24 through. It's not natural to think about asking your
25 doctor, well, how many of those procedures have you done?
26 I mean every time my family needs some help I'm sitting
27 there asking those questions and they're horrified to
28 think about asking a doctor those very specific questions.

1 But I am absolutely encouraged that we can bring people
2 along.

3 I have wild ideas that, for instance, I --
4 if I had my way if somebody made me czarina today, I would
5 get the plans together in one room and say let's simply
6 commit an amount of money to public education over the
7 next five years that involves using the media, television,
8 written, every way we can think of talking about quality,
9 of talking about managed care.

10 I approached some leadership almost seven
11 years ago now and asked them to do that, and I think what
12 we're missing is the fact that there really isn't a broad
13 education effort out there with the public, and if there
14 are ten CHDs we couldn't do this education. It's
15 something that must be committed to, and I'm hoping that
16 that could be one of the things that would come from this
17 Task Force, that we would be willing to sit down with the
18 major players and employers and start putting this
19 information in.

20 DR. RODRIGUES-TRIAS: May I ask a question
21 though on this issue. I think when you look at those
22 outcome they're special study against special studies, you
23 know, three year studies done by some academic
24 institution. I think what we are going to have to grapple
25 with is not just the outcome discussion procedures, which
26 are easier, much easier to do, verses various dimensions
27 in the outpatient and management of somebody to keep them
28 out of the hospital because they're managing their

1 diabetes, that's harder to measure. But how do we get a
2 system that generates some of that information on a
3 regular basis so it's not special studies.

4 MS. FINBERG: I was going to say also I do
5 applaud efforts and agree that life and death is more
6 important than parking. I think we need to have more
7 information and have what information is there out more
8 quickly. There is tremendous resistance to releasing that
9 information, consumers won't understand it. And I find it
10 very patronizing when I hear it said that consumers just
11 want to know about the waiting time or about the parking.
12 We want to know it all. I mean we're all consumers and
13 I'm sure you wouldn't choose your health plan or choose
14 which hospital you went to for your bypass surgery with
15 the information, you know, based on how long it took to
16 wait to get the surgery.

17 So I think consumers need all types of
18 information and, of course, we want the most important
19 information first; that's where health care providers are
20 the stingiest in providing it and protecting themselves
21 for fear of the negative sides of that information being
22 released.

23 But in addition to it being helpful for us
24 to choose, it's also helpful in terms of management. I
25 mean it's certainly true that any provider that scores
26 badly in an area is going to pay attention to that area
27 and try to do better next time.

28 MR. MCDERMOTT: Can I give you the dilemma

1 and put it back on you to think about.

2 We know Clark is absolutely right. We
3 actually know a lot more about outcomes than we're putting
4 out. And since managed care, those studies in the U.S.
5 done in Europe and Canada are much more available today,
6 surprise, surprise, than they used to be 15 years ago. So
7 I shoot off a memo to my chief of cardiology in Sacramento
8 chief of cardiology and attached is the New England
9 Journal study that says if you're doing 70 or more
10 angioplasties a year, you have an extremely better rate of
11 success than if you're doing less than 70. And my note
12 isn't it about time that we limit approval of angioplasty
13 to cardiologists that are doing at least 70 a year. All
14 right.

15 Now we're going to look at that one. Now
16 but think, okay, this uneducated, uninformed public and
17 think about the lawsuits that we will get when I start
18 limiting the practices of cardiologist and or terminating
19 some of the folks that we don't need to do angioplasties
20 any more because we're going to funnel more volume into a
21 fewer amount of people and they're going to do a better
22 job.

23 MR. KERR: So how can we be helpful?

24 MR. MCDERMOTT: Let me terminate.

25 MS. FINBERG: How come you're not afraid of
26 the lawsuits by the bad surgeons?

27 MR. ENTHOVEN: It doesn't seem to happen.

28 MR. MCDERMOTT: I haven't been and we fight

1 those but I'm telling you that's the dilemma we're looking
2 at and that's the issue we're dealing with this week.

3 DR. KARPFF: And how many different states
4 are there than California in developing standardized
5 approach to outcome and publishing? In fact, Pennsylvania
6 state doesn't have much managed care at a time when it had
7 very little managed care put together cost examine council
8 that mandated an information system for everything
9 significant size hospital. It was rather extensive, there
10 was a lot of resistance but they gathered standardized
11 data and they published it on CABG, cardio bypass surgery,
12 on myocardial infarctions and I think, and you're probably
13 much more expert than I, if one tracks that data there has
14 been changes in the variation in that state in facilities
15 because people have responded to that data. So that
16 experiment's been done and people do respond.

17 I think the question is how do you make sure
18 the data is, one, collected; and, two, that it is in fact
19 standardized.

20 MR. ENTHOVEN: You're absolutely right,
21 Michael. New York and Pennsylvania are way ahead of us.
22 You can get their good risk for adjusted mortality for
23 bypass surgery, for example, and you have to be careful
24 not to over interpret. I was in a meeting with Mark
25 Chasen (phonetic) on Monday and he said something about we
26 know Redding Hospital has the lowest mortality rate. He
27 said, yeah, but that was last year. This year they're not
28 so good. So there are problems of interpreting. But I

1 think --

2 DR. KARPf: I should track that. In
3 Philadelphia you track risk adjusted mortality by changing
4 seats of surgeons. So you can make those kind
5 correlations.

6 MR. ENTHOVEN: But I think the experience in
7 New York is there has been substantial progress in risk
8 adjusted mortality and it's put a lot of pressure on poor
9 performers.

10 DR. KARPf: It may be some value to this
11 panel to have some overview of cost containment processes
12 in Pennsylvania and New York and show data. I think we
13 need to get down to the point of looking at some data as
14 opposed to considering anecdotes and personal feelings.

15 MR. ENTHOVEN: Steve.

16 MR. ZATKIN: This discussion does point out
17 the dilemma which is whether the consumer's position is to
18 be protective of the rights of physicians and other health
19 care workers and the rights of patients to have access to
20 them. And one can make certainly make that case, or the
21 freedom of the health care organization, to do what was
22 just pointed out; namely, to try to focus on the best of
23 those providers in terms of volume and so on. And it is
24 not a black or white question. I mean it is a difficult
25 question. The legislature right now is wrestling with it
26 and ultimately, of course, you get a balance. But in
27 terms of the public what you get is pressures at both
28 ends, that is pressure to protect due process and

1 widespread access to all providers, and then at the same
2 time a desire for, appropriately, for enhanced quality,
3 and I just wanted to point that out.

4 MR. ENTHOVEN: Mark.

5 MR. HIEPLER: Does Hill do anything to
6 inform consumers? I think the positive thing is that
7 primary care physician is not capitated.

8 MR. MCDERMOTT: We only started to do that
9 when we began to understand that there was that lack of
10 information so we just started that really within the last
11 three months.

12 MR. HIEPLER: I see that as a very positive
13 thing --

14 MR. MCDERMOTT: And that came out of this.
15 I was sitting with consumers -- I was sitting with Chevron
16 and they didn't, (a) know it nor even understand the
17 implications of it and I'm going whoa.

18 MR. HIEPLER: What we see most of the time
19 and what brings out a suspension of secrecy about the
20 whole HMO industry and some IPAs is they don't know how
21 their doctor is paid, they find out after they've missed a
22 referral, after a tragedy has gone undiagnosed because
23 it's the reverse of what you've described. Generally
24 they're capitated, generally there's huge incentives of
25 one or the other.

26 MR. MCDERMOTT: There is that in the
27 industry.

28 MR. HIEPLER: Sure. Sure. But the consumer

1 doesn't find that out so with the groups that are rare
2 like yours that are incentivizing time and incentivizing
3 the primary care provider to spend time and not
4 disincentivizing, I would think that is a wonderful
5 marketing tool from a positive side because most
6 consumers still think it's fee for service anyway, but
7 those that capitization might have some --

8 MR. MCDERMOTT: On my agenda for the last
9 two years had been to hire a P.R. firm but we've lost
10 money the last three years and so it always makes it off
11 the table.

12 MS. SEVERONI: I would also like to say I
13 don't think we should underestimate the sorry state of
14 managed care today in terms of one of the things Steve
15 said which is this is sort of the first time I sat down
16 with the plan and employer and the enrollee at the table.
17 I mean people are so confused about managed care and why
18 wouldn't they be if this is the state of it. I mean these
19 organizations are all dedicated to providing the best
20 care, the highest quality, and the people in them are all
21 I think very fired up to do that. But if they're not
22 sitting down and having a conversation about how to do
23 that and the only time they're getting together is at the
24 contracting time, where frankly I wouldn't want to be 100
25 feet near those rooms because of the hard balls that get
26 lobbed, I mean it's no wonder consumers are paying for
27 this in some ways.

28 MR. ENTHOVEN: Peter.

1 **MR. LEE:** Tony had his hand up ahead of me,
2 but if I can still make my point.

3 **MR. ENTHOVEN:** I apologize, Tony, I didn't
4 see you.

5 **MR. LEE:** I'm sorry Keith Bishop is gone. I
6 think there's a great example that sort of demonstrates
7 some of the issues raised by these folks and what we got
8 on our desks when we came here is this is lots of numbers,
9 but it's not interpreted in a way that is user friendly
10 for consumers. This is a great, I think, baby step for
11 starting to collect data, but what consumers need is not
12 pages upon pages of numbers but saying some
13 interpretation, some context. And the points on
14 standardization are important, but I think looking at when
15 we think about getting data, whether it's on quality
16 outcomes or about patient satisfaction, are they
17 standardized, where are they coming from, and how are they
18 useful. I think if you flip through this what you as a
19 consumer can say is now I know more about which plan,
20 another plan from these 87 pages of the full service
21 health care service plans. That's an observation point I
22 said in person to Keith so I'm on the record with him on
23 it too.

24 **MR. ENTHOVEN:** Tony, I'm sorry I didn't see
25 you.

26 **MR. RODGERS:** That's okay.

27 The question I have is I'm going to go back
28 to the issue of role of the government verses the role of

1 the market drivers. Certainly you differentiate your
2 product if you have these kinds of processes in place that
3 bring your product forward and you're cooperating with
4 your consumers, etc. I mean that's marketing 101, but
5 because it hasn't happened what's missing. What you
6 talked about incentives where should they come from?
7 Should they come from government which can say if you
8 don't you can get penalized; or do you believe there's
9 enough momentum in the system to drive it in that
10 direction now? The danger with government it becomes so
11 bureaucratic that you lose innovation, you're stuck in a
12 mold. So I'm going to ask you to give us that point of
13 view because that's in essence is where we have to go and
14 what is the role of government in driving these kind of
15 models if they're the right models to use.

16 MS. SEVERONI: I don't have the answer for
17 you yet. I need to spend a little more time with the
18 models themselves. I know that it would be important for
19 instance on the Medi-Cal -- in the Medi-Cal work if we're
20 going to find that this is useful and we want to expand it
21 to the other 12 counties, there's going to have to be some
22 dollars there to do it. And I'm not convinced that it has
23 to be the exact process, the consumer feedback loop
24 process that I showed you today because with each one of
25 these projects we find there's different layers and
26 different ways of doing it, but dollars would have to go
27 there. So if we're looking at the Medi-Cal program my
28 guess would be unless we had a very large private

1 foundation that was willing to put them out there to seed
2 some money that that would have to come from government.

3 MR. ENTHOVEN: One thing is Jeanne and Ellen
4 are expert resource group on this question, and so I think
5 this discussion has been very valuable and I hope it will
6 inspire you to follow that question like this on both
7 arguments. This is very good stuff here. Now how can we
8 translate that into practical resolutions because as you
9 say if you pass a law that says you have to do this people
10 mechanically go through it. You have to generate the
11 spirit, the desire somehow.

12 DR. ROMERO: We certainly want to remove any
13 impediments government regulation imposes unwittingly
14 today that has slowed down the creating of these feedback
15 loops or other mechanisms involved today.

16 MR. ENTHOVEN: I hope they wouldn't have to
17 file a notice of material exchange order.

18 Okay, Bruce, and then we'll have to stop.

19 DR. SPURLOCK: I just have a couple of
20 points. I would just like to echo what I said in San
21 Diego, but I think there is a real seductive nature to
22 information and actually it's in comparison to health care
23 because there's an infinite demand for health care and we
24 always want more. We always want more and more for
25 information too, and there's such a seductive nature that
26 you could make better decisions with more health care
27 information. But the -- like health care costs money and
28 we need to think about the value of giving out health

1 information.

2 In Pennsylvania, where people are looking at
3 this information, the question is how useful is it to
4 consumers? There is a study going on right now to answer
5 that question and it seems like to go forward and collect
6 information and try to gather data without simultaneous
7 looking at the usefulness and the value returned on that
8 is folly, and I think that's what we have to be very, very
9 careful of it otherwise we're going down that pathway.

10 The second point I wanted to make was a
11 little bit about what Clark talked about with the outcomes
12 because I'm involved in CCHRI I sit on the executive --

13 THE REPORTER: You're involved with?

14 DR. SPURLOCK: CCHRI.

15 MR. ENTHOVEN: California Cooperative HEDIS
16 Reporting Initiative.

17 DR. SPURLOCK: We look at outcomes and we
18 look at standardization and we're trying to go into the
19 future, but it looks like there are two different types of
20 reporting initiatives that have to go forward and one type
21 is a general one. It's this data is too much. It's too
22 detailed and we need some kind of general -- something
23 super easy for people to look at from a distance but you
24 also need a detailed report when you're going to have CABG
25 when you're going to have to find out about your surgeon,
26 about your hospital, because that's when it's important.
27 So for the average person knowing the CABG rate is
28 unimportant unless it's going to happen to them. So that

1 information is two types of information general that is
2 really is something that you can go on forever and be very
3 specific so-called drill down information. And I think we
4 have to have parallel efforts to look at both of those
5 arenas and both of those dimensions of quality information
6 because otherwise we're going to spend tons of money.

7 MR. ENTHOVEN: Could the record please show
8 that CABG refers to C-A-B-G, which is an acronym for
9 coronary artery bypass grafts, so we're not talking about
10 vegetables.

11 Thank you very much.

12 With regret but with hunger I propose that
13 we bring that to a conclusion, and if there is no
14 objection I will forego my summarizing May 30th study
15 sessions and we will forego the executive director's
16 report and proceed right away to new business. Is that
17 acceptable? With the incentive of hunger driving everyone
18 we can move quickly.

19 First of all we need to adopt the May 8th,
20 1997, minutes.

21 MR. PEREZ: So moved.

22 MR. KERR: Second.

23 MR. ENTHOVEN: All in favor?

24 COUNCIL GROUP: Aye.

25 MR. ENTHOVEN: It's unanimously moved.

26 Next, adoption of amendments to Task Force
27 bylaws. I would like to ask Alice Singh to briefly
28 discuss the proposed technical amendments.

1 **MS. SINGH:** Basically, members, the
2 amendments are very technical in nature. First of all
3 we're authorizing the chairman to create expert resource
4 groups and to appoint members thereto. Second is to
5 authorize set of rules allowing the assembly speaker to
6 appoint ex-officio members to the Task Force. As I
7 mentioned at our May 8th meeting this was simply an
8 oversight on staff's part in the original conception of
9 the bylaws. And lastly we just have a very technical
10 clarification amendment to address the issue of persons
11 voting on behalf of Task Force members.

12 **MR. PEREZ:** Mr. Chairman --

13 **MS. SINGH:** The amendments are under tab 5
14 (b) and specifically we have amendments on page 2.

15 **MR. PEREZ:** Which are the underline
16 sections?

17 **MS. SINGH:** That's page 1. And if you take
18 a look at your bylaws --

19 **MR. LEE:** I see the changes related to
20 expert resource groups; I see the change for the
21 ex-officio members. What's the change related to voting?

22 **MS. SINGH:** That is underneath the rules on
23 page -- just a moment. It's on page 1 of the standing
24 rules at the bottom, very bottom. It's just a
25 clarification amendment that's made pursuant to the
26 bylaws. The bylaws already stipulate that, we just wanted
27 to make sure our rules corresponded to the bylaws.

28 **MR. ENTHOVEN:** Bruce.

1 **MR. SPURLOCK:** I have some concerns about
2 the first amendment on page 2 that's underlined expert
3 research groups. And we are talking about this morning
4 with some of the Task Force members and I would like to
5 direct -- see if we can make a motion to direct staff with
6 all haste investigate in detail the two task force member
7 limitation to this amendment. And the reason I'm
8 concerned about that is because I'm fearful with only two
9 Task Force members on the resource groups we will limit
10 the perspectives, and when we bring it back here we will
11 recreate the activities by those resource groups and in
12 this kind of environment. So we won't really accomplish
13 the resource group's full understanding of the complete
14 issue. So there has been discussion about the open
15 meeting to action and the absolute litigation on two
16 members and I want to see if we can direct staff to
17 investigate that issue and really have a very clear
18 understanding that that's all we can have. Because two in
19 my mind just doesn't seem broad enough to give us a good
20 resource group perspective.

21 **DR. ROMERO:** Alice, correct my memory if I
22 misremember, but I had this very conversation with you a
23 few weeks ago and I asked in essence what is the basis for
24 the number two and you told me the number is in the
25 legislation as the number two.

26 **MS. SINGH:** The number is in the law and we
27 actually asked Ms. Jennifer D'Sheer (phonetic), who is an
28 attorney that has also helped up interpret this particular

1 act, to verify this particular requirement.

2 UNIDENTIFIED AUDIENCE MEMBER: You can
3 notice the meeting, it's ten days. Surely you can tell
4 the public that you're going to meet in a larger group
5 within ten days' notice. It's not like you can't meet
6 with larger --

7 DR. SPURLOCK: I think we go by conference
8 calls so that's the difference.

9 MR. HAUCK: You can do that if you notice it
10 by the Bagley-Keene Open Meeting Law, state law. You've
11 got to apply the ten day notice --

12 MS. SINGH: Yes, unless you have a group of
13 less than three members that meet.

14 MR. PEREZ: I would like to echo Dr.
15 Spurlock's comments because the information I've received
16 from the legislature is inconsistent with the information
17 I've received here as to the application of the Bagley
18 Open Meeting Law, and what I would like to ask is if we
19 could get some advisory letter either from whatever
20 appropriate body we would seek that input.

21 MR. HAUCK: Get it from counsel.

22 MR. PEREZ: Yeah, because we are receiving
23 inconsistent information regarding the application. And
24 if I may, to differentiate the establishment of
25 subcommittees or working groups and the size of those from
26 conversations between two or more members of a group of 30
27 people, and I think those are slightly different
28 questions, and we may get different answers if we ask

1 those two questions separately.

2 MR. LEE: I'm still baffled that this is
3 really the rule and I strongly support Bruce.

4 The other issue though, as a matter of
5 procedure, I think it's important for all the working
6 groups to circulate material throughout the Task Force and
7 whoever are the chairs of task forces can't serially talk
8 to everyone here, and we don't want to all be talking to
9 everyone all the time, which is hard with nine working
10 groups, but one of the charges of the Task Force Staff and
11 of the process is to circulate drafts of material of the
12 various working groups to get comments funneled back to
13 whoever the working group chairs are. And that's a
14 process suggestion though. I absolutely agree we should
15 get follow-up on being able to talk to more than one
16 person at once.

17 MR. ENTHOVEN: I definitely strongly hope
18 that the people in the expert resource groups will reach
19 out, send drafts to other people, engage them in
20 discussions, get comments, feed them back, and ultimately
21 these papers will be put before the whole Task Force. I
22 find this limitation extremely constraining but given what
23 I was told and understood at the time I figured this is
24 the best way to get around it although -- or deal with it
25 actually, but there's nothing to prevent you from reaching
26 out to several other members on the Task Force and
27 broadening the range of consultation.

28 MR. LEE: Certainly a more formal, I don't

1 know about mandate, but to encourage any Task Force to
2 send and draft everything before it comes to the full Task
3 Force as a proposal to have everyone have an opportunity
4 to say before it gets here for group consideration to have
5 an opportunity to have said why didn't they come up with
6 this.

7 MR. ENTHOVEN: That would be great. That
8 would be excellent if people would do that.

9 MS. SINGH: Anything -- when we prepare our
10 meeting packets that information is available and so
11 reports and so forth would be available in the packets
12 themselves which would also make them available to the
13 public. We just need to keep that in mind. There's
14 nothing that would preclude us from discussing these
15 issues and so forth we just need to do it in a public
16 arena.

17 MR. PEREZ: Serial meetings -- my
18 understanding of serial meetings is that they are held to
19 the same standard as a group meeting.

20 MR. LEE: I don't think serial meetings --
21 if I send out a draft, here's an outline, if people want
22 to send me back comment they can fax it all to me and I
23 can talk to a whole bunch of individuals and they can say
24 Section 5 seems silly why don't you have a whatever.
25 That's a serial meeting, that's people giving comments,
26 isn't it? Sorry.

27 MS. SINGH: It's really a gray area and
28 we've asked our counsel, Dale Bonner (phonetic), to do

1 some extensive research in this particular area because I
2 don't want to say yes or no. I don't feel comfortable
3 doing that, and I've just basically tried to advise the
4 Task Force to be conservative in this respect. I don't
5 want the Task Force to be slapped with some kind of
6 allegation that we're doing something behind the public's
7 eyes. So that's basically --

8 MR. ENTHOVEN: Are you saying though if
9 Peter wants to circulate a draft to a number of people,
10 does that have to be first noticed ahead of time?

11 MS. SINGH: No. He doesn't have to notice
12 that, it's just that it has to be made available to the
13 public.

14 UNIDENTIFIED COUNCIL MEMBER: I would like
15 to encourage the group to think about the tradeoffs
16 between the number of expert resource groups and the
17 public noticing process. If we're going to have expert
18 resource groups that have larger number of Task Force
19 members, which was the original idea, then they simply
20 need to be in a number that's -- we have to have a
21 manageable number of these things. We cannot have an
22 infinite number of expert resource groups that have to be
23 noticed publicly. From a workload standpoint and from a
24 process standpoint it's a waste of managing. So I would
25 urge you if up want to make these larger groups to
26 consider the number of these groups that you want.

27 MR. ENTHOVEN: I'm hoping that though the
28 members of each resource group could try to make it

1 virtual large panel by doing what Peter was suggesting,
2 reach out, send drafts, interact, and, of course, the
3 intent is eventually all of these will go to the full Task
4 Force for discussion.

5 DR. SPURLOCK: I would like to withdraw my
6 earlier motion and change my motion. I want to recommend
7 and make a motion we adopt this amendment; however, I also
8 want to add on that --

9 MS. SINGH: Wait.

10 DR. SPURLOCK: -- we adopt the amendment and
11 we direct staff in clear written detail from counsel the
12 activities that we can do under this process which would
13 be including both written and oral communication between
14 members of the Task Force so we can start this process.
15 We can get the two people going, get that process, and if
16 it looks like we can add on more we can have different
17 processes. But I want to have it written in front of my
18 eyes so I know what I'm doing is in accordance with the
19 law.

20 MR. ENTHOVEN: Could we separate that into
21 two parts? Your first motion was that we approve this --

22 DR. SPURLOCK: Amendment, page 2.

23 MS. SING: Wait. I'm sorry. I just need to
24 get some clarification here. First of all, who made --
25 did anybody make a motion? Nobody made a motion to even
26 adopt the rule.

27 MR. HAUCK: He just did.

28 MR. ENTHOVEN: He just did.

1 **MS. SINGH:** Okay. Now we have a second?

2 **MR. HAUCK:** I second.

3 **MR. PEREZ:** I got a question. Was the
4 motion to adopt the specific amendment with respect to
5 these groups or was the motion to adopt all of the
6 amendments that are before us?

7 **MR. ENTHOVEN:** Just this one. Just this one
8 on expert resource group.

9 **MS. SINGH:** So you're moving to adopt the
10 amendments to the expert resource groups as is; is that
11 correct?

12 **DR. SPURLOCK:** Correct. And we have --

13 **MS. SINGH:** So what we have to do is we have
14 to have a separate motion. We need a separation motion to
15 do that. I'm sorry, I want to make sure everybody is
16 clear and I'm clear.

17 **MR. PEREZ:** Might I suggest we make -- maybe
18 I can recommend a friendly amendment. If you strike on
19 the second line of that paragraph, if you strike the "of
20 no more than two," then the chair has the flexibility to
21 compose these groups of two members, if that's the
22 information we received back as being the legal limit, or
23 more than two members, if we chose based information or
24 based on a desire to notice the meetings to compose them
25 of more than two members.

26 **MR. LEE:** I second that amendment.

27 **MR. PEREZ:** If it's friendly it doesn't need
28 to be seconded.

1 **MR. LEE:** And also to amend the last
2 sentence saying if --

3 **MS. SINGH:** Wait.

4 **MR. LEE:** I'm sorry, the last sentence of
5 the first full paragraph if expert resource groups contain
6 more than two Task Force members, they shall be subject to
7 all appropriate -- yada, yada. And we're still going to
8 have your follow-up motion to clarify what that means.

9 **MR. ENTHOVEN:** So it would say if expert
10 resource groups contain more than two Task Force members
11 the noticing provisions of Government Code --

12 **MR. LEE:** Do apply.

13 **MR. ENTHOVEN:** Do apply. Both friendly
14 amendments.

15 **MS. SINGH:** Is there a second to that?

16 **MR. HAUCK:** Second.

17 **MR. ENTHOVEN:** All in favor?

18 **COUNCIL MEMBERS:** Aye.

19 **MS. SINGH:** I'm sorry, first we're going to
20 vote on the last amendment which was Mr. Lee's amendment,
21 okay. So we're clear on that that's what we're voting on
22 first which was to add language into the expert resource
23 section stating that if there are more than two members
24 that meeting will be noticed.

25 **MR. HAUCK:** Let me just say that if we
26 continue to proceed in this sort of fashion in terms of an
27 absolute adherence to the technical requirements of
28 Robert's Rules of Order, we're going to tire ourselves in

1 so many knots that it is outrageous and we don't have to
2 do that. And in this instance we can vote to approve the
3 motion and the amendment together and the minutes can
4 reflect that the motion to approve the -- the motion and
5 the amendment was approved unanimously by the Task Force
6 or whatever the vote maybe.

7 MR. LEE: Second.

8 MS. SINGH: I don't mean to be -- I guess --

9 MR. HAUCK: Alice, I know you don't mean to
10 be but you are.

11 MR. ENTHOVEN: Alice, just do it.

12 That takes care of expert resource groups.

13 Now we've got these other amendments.

14 MR. HAUCK: Mr. Chairman, on the second one,
15 are we there now? The second one is the ex-officio
16 members from rules and assembly?

17 MR. ENTHOVEN: Yeah.

18 MR. HAUCK: We've demonstrated more than
19 once how difficult it is to conduct a discussion with a
20 group that's this size. If we add more, I don't care
21 where they're from and I don't care if they can't vote, if
22 they can participate in a discussion all we do is add to
23 the difficulty of what is already a very difficult
24 situation in terms of having meaningful discussions when
25 we have membership of 30 people. And as a practical
26 matter even the limitations on the time the Task Force has
27 to function. I think adding any more people as
28 participants in the discussion is going to make our job

1 just more difficult.

2 MR. KERR: Is there any number of
3 suggestions to limit there?

4 MR. ENTHOVEN: Well, I thought this was
5 ratifying what had apparently been a fait accompli.

6 MS. FINBERG: I think we adopted this
7 principal.

8 MR. KERR: I don't have a problem if we are
9 adding 50 people.

10 MS. FINBERG: Why don't we say no more than
11 five.

12 MS. BOWNE: No more than two.

13 MR. PEREZ: Mr. Chairman, the roster I
14 received at our last meeting in Sacramento listed several
15 ex-officio members on the back, some of whom hadn't truly
16 been seated because the bylaws didn't allow for them to be
17 seated. But, for example, it listed Senator Herschel
18 Rosenthal as an ex-officio even though those bylaws hadn't
19 allowed for him. So aren't we really changing the bylaws
20 to allow for people that we already -- who have already
21 been involved in this process to be recognized as
22 ex-officio members?

23 MR. ENTHOVEN: That's my understanding of
24 what we're doing.

25 MS. BOWNE: But potentially you're opening
26 it up for them to nominate as many more persons --

27 DR. ROMERO: Which is why the next
28 amendment.

1 **MS. FINBERG:** That's why we'll add but no
2 more than five.

3 **UNIDENTIFIED COUNCIL MEMBER:** Seven is fine.

4 **MR. PEREZ:** There's eight here but some of
5 them were already allowed by the governor.

6 **MR. LEE:** Some of them are mandated.

7 **MR. PEREZ:** Right. I think five would --

8 **DR. ROMERO:** Mr. Chairman, first of all it's
9 accurate that this is a technical amendment simply to
10 ratify the establishment. The legislature also has the
11 authority to appoint ex-officio members. It was an
12 oversight in the original drafting. The governor
13 appointed a few, the legislature hadn't appointed anybody
14 yet, so we can fix that. I think I would recommend that
15 the Task Force put a limit of either an actual number or
16 in essence a balance between gubernatorial and legislative
17 appointees.

18 **DR. SPURLOCK:** I want to make a motion to
19 amend the amendment. And I'm going to say that the Senate
20 Rules Committee and Assembly Speaker may appoint
21 ex-officio members and that the roster of the Task Force
22 will be complete and closed as of June 30th, 1997.

23 **MS. FINBERG:** That might be a little bit
24 restrictive if there's a change in personnel or a
25 particular issue within a department. So we ought to give
26 a little leeway, not a lot.

27 **MR. HAUCK:** Why don't we eliminate
28 ex-officio members.

1 **MR. LEE:** No offense under the table there.

2 **MS. BELSHE':** I made that suggestion to

3 Bill; I was kidding.

4 **MS. FINBERG:** She wants to go home.

5 **MR. ENTHOVEN:** Is that in the legislation?

6 **MR. HAUCK:** It says may or your rules say it

7 may, I don't know --

8 **DR. ROMERO:** A bit of history for context.

9 When the legislation specified that the governor had 20

10 appointments and the legislature had ten, five each, the

11 governor felt it was important that certain department

12 heads who have direct responsibility for regulation or

13 health policy be representative of the Task Force, ergo

14 four or five governor's ex-officio appointments, the

15 legislature has responded and appointed two -- is that all

16 we have is two? I prefer to defer to the ex-officios, but

17 I guess one has already spoken. I can certainly find ways

18 to assure you folks add value even if you're not at the

19 table.

20 **MS. BELSHE':** I personally think there is

21 value in having ex-officios, it's just you've got more of

22 a political issue with our legislative leadership and the

23 suggestion of having their be parity in gubernatorial --

24 **MR. LEE:** I move that as a suggestion.

25 There may be up to parity with whatever is appointed by

26 the governor.

27 (Whereupon a discussion was had among the

28 council members that the reporter was unable to take

1 down.)

2 MR. HAUCK: Based on this list there are
3 one, two, three, four, five, executive branch ex-officio
4 members and currently there are two legislative, Senator
5 Rosenthal and Michael Shapiro. So if you had a total of
6 eight legislative ex-officio --

7 MR. LEE: No, between Assembly and Senate.
8 Between parity adding together Senate and Assembly they
9 each get half of what the governor gets.

10 DR. ROMERO: That was generous because they
11 get only half of the total number.

12 MR. HAUCK: That's an odd -- I mean you
13 have -- you -- now have five executive branch --

14 DR. ROMERO: So three.

15 MR. ENTHOVEN: Two and a half.

16 MR. HAUCK: Two and a half.

17 MR. ENTHOVEN: Do you want to make a motion
18 to do this?

19 MR. LEE: Motion is to allow for --

20 MR. ENTHOVEN: Call up Peter here.

21 MR. LEE: -- the Assembly and Senate may
22 appoint up to between them the same number of ex-officios
23 appointees as the governor, but no more. And they're not
24 mandated to do so.

25 MR. ENTHOVEN: Okay. That's the motion.

26 All in favor?

27 COUNCIL MEMBERS: Aye.

28 MR. ENTHOVEN: Anyone opposed?

1 **Let's see. Does that do the --**

2 **MR. PEREZ: I have --**

3 **MR. ENTHOVEN: John, yeah.**

4 **MR. PEREZ: The next amendment is to the**
5 **standing rules as opposed to the bylaws. I have a couple**
6 **of issues to raise with respect to the bylaws that I would**
7 **like us to deal with, if I may.**

8 **On page 4 of the bylaws first paragraph it**
9 **basically says that the procedure for publishing or**
10 **releasing or attributing information is solely the**
11 **discretion of the executive director. And I don't find**
12 **that to be an acceptable rule to govern the publication of**
13 **findings of a group this size. And I think we should**
14 **strike approval of the executive director and replace that**
15 **with approval of the Task Force.**

16 **DR. ROMERO: I don't understand your**
17 **objection.**

18 **MR. PEREZ: I'm not saying this would**
19 **happen, but it could happen, we could make a vote 25, 5 on**
20 **this report and you could say no.**

21 **MR. ENTHOVEN: I don't think that was the**
22 **intent. The intent was to have editor-in-chief, a traffic**
23 **cop, so that it was clear what had to --**

24 **MR. PEREZ: Right. And that's why the**
25 **executive director makes written and other reports back to**
26 **this body, and I think that the appropriate way would be**
27 **for the executive director and the staff to draft things**
28 **that they would like to be published or to fine tune**

1 things that we would like to be published. But ultimately
2 this body should have the authority to publish findings as
3 we see fit by majority vote.

4 DR. ROMERO: The distinction is between
5 editing and the production process verses the publication
6 of vote.

7 MR. PEREZ: No, I think it's approval. It
8 says -- it specifically says shall be approved, and I
9 think that the approval should lie with the majority of
10 the members of the Task Force.

11 MR. LEE: Can I suggest a friendly amendment
12 to that? The law of the intent here, I think, is not
13 having Task Force members doing individual things and
14 saying I'm speaking for the Task Force. I understand your
15 intent. I would suggest an amendment that says -- where
16 it says materials distributed by the Task Force shall be
17 approved by -- insert a majority vote of the Task Force or
18 the Task Force executive director. I don't think we're
19 trying to stop a press release or formal announcement.

20 MR. PEREZ: That's definitely better.

21 And while we're on that one section if I
22 might add one other thing. In the next paragraph it is
23 says the views -- and it explains what disclaimers shall
24 be accompanied by publications by individuals. I would
25 like to insert the word necessarily so that instead it
26 would say views expressed herein -- actually drop the word
27 exclusively and insert the word necessarily. So it would
28 read views expressed herein aren't of the author and do

1 not necessarily represent the view or opinions of the
2 Managed Health Care Improvement Task Force.

3 DR. ROMERO: That's much closer to standard
4 disclaimer language.

5 MR. ENTHOVEN: Is that a motion?

6 MR. LEE: Yes.

7 MR. ENTHOVEN: Second?

8 MR. RODGERS: Second.

9 MR. ENTHOVEN: All in favor?

10 COUNCIL MEMBERS: Aye.

11 MR. ENTHOVEN: Any opposed?

12 MS. FINBERG: I have a question now. If the
13 majority is approving written materials like the final
14 document, if in the event we're not in unanimous in our
15 written product, would that allow for a minority report.

16 MR. ENTHOVEN: Certainly. Absolutely.

17 MS. FINBERG: But it would have to be
18 approved by the whole Task Force, I think. That's what
19 I'm wondering if we don't need to indicate or minority
20 reports may also be published or something like that.

21 MR. ENTHOVEN: Jeanne, I would like to say
22 the intent certainly in my mind has been from the outset
23 that minority reports -- we don't want to try to
24 represent, to represent to the world anything different
25 than what is a fact, you know, and I'm expecting in some
26 cases 25 members approve the following recommendations and
27 "X" number of members have the following different view
28 which is presented to the --

1 **MS. FINBERG:** But does this allow for that?

2 **MR. LEE:** This allows for it at least by
3 saying the views of these five members don't represent the
4 whole Task Force but could be specifically allowed even
5 with that caveat. The members of a minority view could be
6 covered right here.

7 **MR. PEREZ:** The other process, right, is
8 that the approval of a report -- we as a body can approve
9 a report with both majority and minority report in the
10 same body so that for example if several of us didn't
11 agree with the majority report, we could attach that so
12 that both reports are shared collectively and then a
13 majority vote would be required to approve both things
14 together.

15 **MR. ENTHOVEN:** But I think it goes without
16 saying that our duty is to disclose majority views and
17 minority views. We don't want to sweep any ideas under
18 the rug.

19 **MS. FINBERG:** Good. I don't have to make a
20 motion then.

21 **MR. PEREZ:** I have one last issue that I
22 would like to raise. With respect to order of business on
23 page 4 where it says the agenda for regular business
24 meeting shall be set by the executive director. Again,
25 there I would like to say executive director or majority
26 vote of the Task Force.

27 **MR. LEE:** Second.

28 **MR. ENTHOVEN:** All in favor?

1 **COUNCIL MEMBERS: Aye.**

2 **MR. ENTHOVEN: Opposed?**

3 **Done.**

4 **MS. SINGH: We still need to vote on the**
5 **amendment the standing rule in accordance with Task Force**
6 **bylaws ex-officio members -- we're adding and other**
7 **persons may not vote on actions before the Task Force.**
8 **We're adding and or on behalf of the Task Force member.**

9 **DR. ROMERO: A proxy in other words.**

10 **UNIDENTIFIED COUNCIL MEMBER: So moved.**

11 **MR. PEREZ: Second.**

12 **MR. ENTHOVEN: All in favor.**

13 **COUNCIL MEMBERS: Aye.**

14 **MR. ENTHOVEN: Finally, we must leave some**
15 **time for public comment, we may have exhausted the members**
16 **of the public. And if members of the public want to**
17 **comment we will be meeting at two o'clock here. It would**
18 **be nice if the comments were postponed until then so the**
19 **Task Force members can get something to eat, but if**
20 **Estella Martinez or Ray Ensher want to speak now -- I**
21 **apologize for the intimidation here but they may do so or**
22 **alternatively they can speak to happier better fed Task**
23 **Force members.**

24 **UNIDENTIFIED AUDIENCE MEMBER: I would**
25 **prefer to speak to the better fed.**

26 **MR. LEE: I'm sorry, I want to eat a lot**
27 **too, not a lot. The Task Force resource groups was last**
28 **on the agenda and I would be curious if we have these**

1 paired already and maybe you were going to distribute
2 something or let us know more about the draft we got.

3 MR. ENTHOVEN: We have in the meeting packet
4 the list of groups and now I have here -- I've been
5 working it out and it would have been made available to
6 you sooner except that I still haven't gotten yeses on
7 either writing or trying to speak to people and playing
8 telephone tag and I think probably, and in most cases but
9 not all have gotten agreement. Why don't I just --

10 MR. LEE: Send it out.

11 MR. ENTHOVEN: Send it out. We have 14
12 groups, some of them are two person groups; they can meet
13 together. Some are larger which we're thinking can serve
14 as a review panel. But let me emphasize to you the value
15 of people reaching out to achieve balance. I've tried to
16 achieve some -- there's several objectives one is capture
17 expertise and another is achieve some balance. So I will
18 fax this out early next week where we stand.

19 DR. ROMERO: Two background comments,
20 Mr. Chairman.

21 The first one is to echo what Hattie was
22 saying earlier when we were discussing bylaw amendments.
23 There are 12 of them -- 14, sorry, 14 groups, each of them
24 had relatively narrow boundary problems, although you
25 might not think that when you get involved with your
26 specific effort, that was to try to make the work
27 handleable with a small number of people. If we -- if you
28 ultimately decide that you need to go to larger problems

1 and more inclusive groups, then we have the option of
2 noticing them.

3 The point that I think Hattie was implying
4 and I want to emphasize is that -- and with respect to
5 staff, I just can't be in the position of noticing 14
6 groups. I can be the position of noticing two or three or
7 four groups or some small number like that. So if you get
8 more inclusive in the processes, you'll have to get more
9 ambitious about identity.

10 The second comment I want to make, I'll put
11 this in writing but an investigative structure has been
12 suggested to me and I just want to mention now and I will
13 re-emphasize in a letter later I suggest that each of
14 these groups try to answer three questions. And the
15 questions are -- I need my notes. The questions are first
16 of all what is the real or perceived problem that this
17 group is attempting to solve? And then there's some
18 investigation to distinguish perceived from real,
19 obviously.

20 The second question is what gaps or
21 deficiencies are there in the market and governing
22 structure that's causing that problem or not ameliorating
23 that problem.

24 And then the third is what roles should
25 various market participants take, i.e., purchasers, plans,
26 consumers, providers, and government to try to address
27 that deficiency.

28 And then the fourth and final goal which

1 final question will be a topic of one particular expert
2 resource group that is in essence then how should
3 government organize to fulfill its particular role?

4 Again, I will -- this is -- I will be
5 summarizing this more thoughtfully in writing, but I
6 wanted to introduce these to you now.

7 MR. PEREZ: Could you repeat the third one.

8 DR. ROMERO: Yeah. Third one was in
9 essence -- I won't use exact same words because I don't
10 remember them -- but in essence what role should the
11 various participants in the market and government play in
12 fixing the problem, and as I mentioned were plans,
13 consumers, providers, and employer and purchasers. And I
14 mention that one just to make the point that even though
15 our function is the role of government, I always want to
16 remind ourselves that government's role is simply in the
17 context of the role. It's a number of different
18 participants in this market.

19 MR. ENTHOVEN: Jeanne, did you have a --

20 MS. FINBERG: I'll mention it privately so
21 we can eat.

22 MR. ENTHOVEN: Without objection the meeting
23 is adjourned and we will reconvene at two o'clock.

24 * * *

25

26

27

28

